

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>(51) International Patent Classification <sup>5</sup> :</b><br>A01N 63/00, A61K 37/02, 39/00<br>C07K 15/08, 15/14, 15/28<br>C12N 5/06, 15/12, C12Q 1/68<br>G01N 33/53                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 93/19605</b><br><br><b>(43) International Publication Date:</b> 14 October 1993 (14.10.93)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>(21) International Application Number:</b> PCT/US93/02936<br><b>(22) International Filing Date:</b> 6 April 1993 (06.04.93)<br><b>(30) Priority data:</b><br>07/863,262 6 April 1992 (06.04.92) US<br>07/987,966 11 December 1992 (11.12.92) US<br>08/031,434 15 March 1993 (15.03.93) US<br>08/034,832 17 March 1993 (17.03.93) US<br><b>(60) Parent Applications or Grants</b><br><b>(63) Related by Continuation</b><br>US 08/034,832 (CIP)<br>Filed on 17 March 1993 (17.03.93)<br>US 08/031,434 (CIP)<br>Filed on 15 March 1993 (15.03.93)<br>US 07/863,262 (CIP)<br>Filed on 6 April 1992 (06.04.92)<br>US 07/987,966 (CIP)<br>Filed on 11 December 1992 (11.12.92)<br><b>(71)(72) Applicants and Inventors:</b> OCHOA, Augusto, C. [CO/US]; 3872 Porter Street, N.W., Apt. F-360, Washington, DC 20016 (US). MIZOGUCHI, Hiromoto [JP/US]; 149 Willowdale Drive, Apt. 44, Frederick, MD 21702 (US). O'SHEA, John, J. [US/US]; 1721 Dublin Drive, Silver Spring, MD 20902 (US). LONGO, Dan, L. [US/US]; 9610 Barroll Lane, Kensington, MD 20895 (US). LOEF-FLER, Cynthia, M. [US/US]; 5151 North 9th Avenue |           | Avenue, Pensacola, FL 32513 (US). GHOSH, Paritosh [IN/US]; 200 Ashford Court, Frederick, MD 21702 (US). YOUNG, Howard, A. [US/US]; 1420 Stonebridge View Drive, Gaithersburg, MD 20878 (US).<br><b>(74) Agents:</b> SAXE, Bernhard, D. et al.; Foley & Lardner, 3000 K Street, N.W., Suite 500, P.O. Box 25696, Washington, DC 20007-5109 (US).<br><b>(81) Designated States:</b> AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).<br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> EVALUATION AND TREATMENT OF PATIENTS WITH PROGRESSIVE IMMUNOSUPPRESSION<br><br><b>(57) Abstract</b><br><br>A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels, T lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, a protein in the T lymphocyte signal transduction pathway, or of the NF- $\kappa$ B/rel family and comparing the level and pattern to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.                                               |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria                  | FR | France                                | MR | Mauritania               |
| AU | Australia                | GA | Gabon                                 | MW | Malawi                   |
| BB | Barbados                 | GB | United Kingdom                        | NL | Netherlands              |
| BE | Belgium                  | GN | Guinea                                | NO | Norway                   |
| BF | Burkina Faso             | GR | Greece                                | NZ | New Zealand              |
| BG | Bulgaria                 | HU | Hungary                               | PL | Poland                   |
| BJ | Benin                    | IE | Ireland                               | PT | Portugal                 |
| BR | Brazil                   | IT | Italy                                 | RO | Romania                  |
| CA | Canada                   | JP | Japan                                 | RU | Russian Federation       |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CG | Congo                    | KR | Republic of Korea                     | SE | Sweden                   |
| CH | Switzerland              | KZ | Kazakhstan                            | SK | Slovak Republic          |
| CI | Côte d'Ivoire            | LJ | Liechtenstein                         | SN | Senegal                  |
| CM | Cameroon                 | LK | Sri Lanka                             | SU | Soviet Union             |
| CS | Czechoslovakia           | LU | Luxembourg                            | TD | Chad                     |
| CZ | Czech Republic           | MC | Monaco                                | TC | Togo                     |
| DE | Germany                  | MG | Madagascar                            | UA | Ukraine                  |
| DK | Denmark                  | ML | Mali                                  | US | United States of America |
| ES | Spain                    | MN | Mongolia                              | VN | Viet Nam                 |
| FI | Finland                  |    |                                       |    |                          |

**EVALUATION AND TREATMENT OF PATIENTS  
WITH PROGRESSIVE IMMUNOSUPPRESSION**

**BACKGROUND OF THE INVENTION**

5           The present application is a continuation-in-part application of U.S. Serial No. 07/863,262, filed April 6, 1992, and U.S. Serial Number 07/987,966, filed December 11, 1992.

10           The invention relates to a soluble immunosuppressive factor produced by cells of a tumor-bearing mammal and to a gene encoding said factor. Screening methods for agents inhibiting or reversing the action of this factor are identified. Immunosuppressive agents and counter-  
15           agents are recognized using the invention. The factor may be used to induce immunosuppression. The present invention also relates to the evaluation, selection and treatment of patients with diseases causing progressive immunosuppression. Patients having a disease responsive to immunotherapy, especially cancer patients, are staged  
20           or evaluated based on expression levels of proteins affected by immunosuppression. The likelihood of success of such immunotherapy is predicted by the results of staging and evaluation.

25           Many diseases are characterized by the development of progressive immunosuppression in a patient. The presence of an impaired immune response in patients with malignancies has been particularly well documented. Cancer patients and tumor-bearing mice have been shown to have a variety of altered immune functions such as a  
30           decrease in delayed type hypersensitivity, a decrease in

lytic function and proliferative response of lymphocytes. S. Broder et al., *N. Engl. J. Med.*, 299: 1281 (1978); E.M. Hersh et al., *N. Engl. J. Med.*, 273: 1006 (1965); North and Burnauker, (1984).

5        Many other diseases are also characterized by the development of an impaired immune response. For example, progressive immunosuppression has been observed in patients with acquired immunodeficiency syndrome (AIDS), sepsis, leprosy, cytomegalovirus infections, malaria, and  
10    the like. The mechanisms responsible for the down-regulation of the immune response, however, remain to be elucidated.

      The immune response is a complex phenomenon. T lymphocytes (T cells) are critical in the development of  
15    all cell-mediated immune reactions. Helper T cells control and modulate the development of immune responses. Cytotoxic T cells (killer T cells) are effector cells which play an important role in immune reactions against intracellular parasites and viruses by means of lysing  
20    infected target cells. Cytotoxic T cells have also been implicated in protecting the body from developing cancers through an immune surveillance mechanism. T suppressor cells block the induction and/or activity of T helper cells. T cells do not generally recognize free antigen,  
25    but recognize it on the surface of other cells. These other cells may be specialized antigen-presenting cells capable of stimulating T cell division or may be virally-infected cells within the body that become a target for cytotoxic T cells.



Cytotoxic or suppressor T cells usually recognize antigen in association with class I Major Histocompatibility Complex (MHC) products which are expressed on all nucleated cells. Helper T cells, and  
5 most T cells which proliferate in response to antigen *in vitro*, recognize antigen in association with class II MHC products. Class II products are expressed mostly on antigen-presenting cells and on some lymphocytes. T cells can be also divided into two major subpopulations  
10 on the basis of their cell membrane glycoproteins as defined with monoclonal antibodies. The CD4<sup>+</sup> subset which expresses a 62 kD glycoprotein usually recognizes antigen in the context of class II antigens, whereas the CD8<sup>+</sup> subset expresses a 76 Kd glycoprotein and is  
15 restricted to recognizing antigen in the context of Class I MHC.

The CD4<sup>+</sup> subset can be further subdivided into two functionally distinct groups. One group of cells positively influences the immune response of T cells and  
20 B cells. The second group of cells induces suppressor/ cytotoxic functions in CD8<sup>+</sup> cells.

The definitive T cell marker is the T cell antigen receptor (TCR). TCR-2 is a heterodimer of two disulfide-linked polypeptides ( $\alpha$  and  $\beta$ ). TCR-1 is structurally  
25 similar to TCR-2, but consists of  $\gamma$  and  $\delta$  polypeptides. Both TCR-1 and TCR-2 are associated with a complex of polypeptides which comprise the CD3 complex.

The TCR found on the surface of all T cells is composed of at least six different subunits which can be

divided into three distinct subgroups of proteins. R.D. Klausner et al., *Annu. Rev. Cell Biol.*, 6: 403 (1990).

The Ti subunits are responsible for antigen binding, and include the  $\alpha$ ,  $\beta$ ,  $\gamma$  and  $\delta$  chains. The heterodimers  $\alpha\beta$  or  $\gamma\delta$  within the receptor complex are responsible for ligand binding. The  $\alpha\beta$  heterodimer is found on most mature T cells and the  $\gamma\delta$  heterodimer is found predominantly on T cells that are located in epithelia.

Another subgroup of proteins which comprise the TCR are the CD3 chains which encompass at least four distinct, but closely related subunits. These subunits are  $\gamma$ ,  $\delta$ ,  $\epsilon$  and  $\zeta$ . F. Koning et al., *Eur. J. Immunology*, 20: 299 (1990); R.S. Blumberg et al., *Proc. Natl. Acad. Sci. USA*, 87: 7220 (1990). Diversification of receptor types is the result of segregation of chains of the TCR complex into multiple subunits. Incompletely assembled complexes are degraded, resulting in the surface expression of only completely assembled receptors. R.D. Klausner, *New Biol.*, 1: 3 (1989).

In addition to the involvement of the TCR subunit proteins, T cell recognition events lead to signal transduction and appropriate biochemical signals that control cellular responses. The ability of TCR to transduce signals to multiple biochemical cascades is a central event of immune cell activation. The details of this signal transduction pathway, however, are poorly understood. For the TCR, one or more tyrosine (Tyr) kinases likely have an essential role in T cell activation. R.D. Klausner et al., *Cell*, 64: 875 (1991).

At least two signal transduction pathways are activated upon stimulation of TCR by an antigen or by monoclonal antibodies directed against either CD3 or the  $\alpha\beta$  heterodimer.

5           Stimulation of TCR activates a tyrosine kinase. L.E. Samelson et al., *Cell*, 46: 1083 (1986); M.D. Patel et al. *J. Biol. Chem.*, 262: 5831 (1987); E.D. Hsi et al., *J. Biol. Chem.*, 264: 10836 (1989). Phosphorylation of several proteins with tyrosine residues is induced within  
10 seconds of TCR stimulation. C.H. June et al., *J. Immunol.*, 144: 1591 (1990). None of the TCR chains possesses intrinsic kinase activity. A member of the Src family of tyrosine kinases designated Fyn, however, coprecipitates with the CD3 complex. L.E. Samelson et  
15 al., *Proc. Natl. Acad. Sci. USA*, 87: 4358 (1990). A T cell specific member of the Src family of tyrosine kinases, Lck, is tightly, but non-covalently, associated with the cytoplasmic domain of either a CD4 or CD8 molecule. The extracellular domains of CD4 and CD8 bind  
20 to MHC class II and class I molecules, respectively. Upon binding of TCR to an antigen-MHC complex on a presenting cell, the TCR is believed to be brought into close proximity with either a CD4 or CD8 molecule that is capable of independently binding to an appropriate MHC  
25 molecule.

TCR also activates a phosphatidylinositol-specific phospholipase C which leads to hydrolysis of phosphatidylinositol-4,5-bis-phosphate. A. Weiss et al., *Proc. Natl. Acad. Sci. USA*, 81: 4169 (1984); J.B. Imboden

et al., *J. Exp. Med.*, 161: 446 (1985). This leads to the liberation of two second messengers: 1) inositol-1,4,5-tris-phosphate which is responsible for transient  $\text{Ca}^{2+}$  mobilization; and 2) diacylglycerol which is a potent activator of protein kinase. C.B. Berridge et al., *Nature*, 341: 197 (1989).

The cytoplasmic domain of the TCR  $\zeta$  chain is sufficient to couple stimulation of the receptor with the signal transduction pathways. B.A. Irving et al., *Cell*, 64: 891 (1991). When a chimeric protein linking the extracellular and transmembrane domains of CD8 to the cytoplasmic domain of the  $\zeta$  chain was constructed, the chimeric protein activated the appropriate signal transduction pathways in the absence of CD3  $\gamma$ ,  $\delta$ , and  $\epsilon$ . Therefore the role of  $\zeta$  is apparently to couple the TCR to intracellular signal transduction mechanisms.

Another set of proteins that are related to signal transduction are the NF- $\kappa$ B/rel transcription factors. The NF- $\kappa$ B transcription activator is a multiprotein complex. The NF- $\kappa$ B transcription activator appears to have specialized in the organism to rapidly induce the synthesis of defense and signalling proteins upon exposure of cells to a wide variety of agents including cytokines, double-stranded RNA, T cell mitogens, DNA damaging agents, protein synthesis inhibitors, parasites, viruses and viral transactivators. A common denominator of the agents that activate NF- $\kappa$ B is that they either signal or represent a threat to cells and the organisms.

NF- $\kappa$ B is particularly suited to rapidly activate gene expression because (1) it does not require new protein synthesis, (ii) a simple dissociation reaction triggers activation, (iii) NF- $\kappa$ B actively participates in cytoplasmic-nuclear signalling and (iv) it is a potent transactivator.

NF- $\kappa$ B is involved in the inducible expression of the T cell growth factor interleukin-2 and a component of its high affinity receptor suggesting that NF- $\kappa$ B can be a growth regulator. There is indeed a good correlation between the proliferative state of T cells and the state of NF- $\kappa$ B activity.

Three protein subunits, I $\kappa$ B, p50 and p65 control the biological functions of NF- $\kappa$ B. I $\kappa$ B is a 35-43 kDa subunit which inhibits the DNA-binding of NF- $\kappa$ B and serves to retain NF- $\kappa$ B in an inducible form in the cytoplasm of unstimulated cells. Upon stimulation of cells, I $\kappa$ B dissociates from the inactive complex with p65 and p50. The released p50-p65 complex heterodimer then migrates into the nucleus and trans-activates genes. Constitutive expression of the IL-2 receptor  $\alpha$  gene in hybrids between a T-cell and myeloma cell line depends solely on the presence of the heterodimer. Only p65 appears to bind I $\kappa$ B. Within cells, I $\kappa$ B could be released by modification of either I $\kappa$ B, p65, or both.

Rel proteins are believed to be transcriptional activators, are capable of forming heterodimers with p50, and are sequence-specific DNA binding proteins which are capable of recognizing  $\kappa$ B motifs. I $\kappa$ B is a member of a

family of proteins that share homologies and apparently play a similar role in the cell. Both p50 and p65 have homologies to the rel and dorsal proteins. The I $\kappa$ B-family and rel-family therefore comprise related proteins which are known to be involved in cytoplasmic/nuclear signalling.

Other information on the NF- $\kappa$ B transcription activator and its relationship to the rel proteins may be found in Baeuerle, P.A. (1991), "The inducible transcription activator NF- $\kappa$ B regulation by distinct protein subunits", *Biophysica Acta* 1072:63-80.

Chemotherapy as a treatment modality has not been successful for all types of cancer. The identification and isolation of soluble mediators of the immune response has heightened interest in the development of clinical trials using immunotherapy as an alternative form of treatment. For example, biological response mediators (BRM) such as interleukin-2 (IL-2), a lymphokine produced by helper T cells, stimulates the growth of T cells that bear IL-2 receptors, either *in vivo* or *in vitro*. It also activates (enhances) the anti-tumor function of natural killers (NK) cells (Lotze et al. 1981). NK cells also express the  $\gamma$  chain. The *in vitro* incubation of resting lymphocytes in supernatants containing IL-2 for three to four days results in the generation of lymphocytes capable of mediating the lysis of fresh tumor cells, but not of normal cells. These lysing cells are referred to as lymphokine activated killer (LAK) cells. I. Yron et al., *J. Immunol.*, 125: 238 (1980); M.T. Lotze et al.,

*Cancer Res.*, 41: 4420 (1981); and S.A. Rosenberg et al., *J. Natl. Cancer Inst.*, 75: 595 (1985).

A method for the activation of T lymphocytes to generate T-activated killer cells (T-AK) has been described as taking lymphocytes by leukophoresis or from peripheral blood, and stimulating said cells with a monoclonal antibody (MAb) to a T cell surface receptor such as anti-CD3 (soluble or solid phase bound). The T cells can be stimulated with or without the addition of one or more cytokines such as IL-2. Alternatively, T cells can be purified before stimulation with the MAb to a surface receptor. Experimentation with T-AK cells has demonstrated that CD8<sup>+</sup> cells are responsible for the non-MHC restricted cytolytic activity seen in these cultures. P.M. Anderson et al., *J. Immunol.*, 142: 1383 (1989); C.M. Loeffler et al., *Cancer Res.*, 51: 2127 (1991). The ability of IL-2 to expand T lymphocytes having immune reactivity and the ability to lyse fresh autologous, syngeneic, or allogeneic natural killer (NK) cell-resistant tumor cells, but not normal cells, has resulted in the development of cell transfer therapies, such as autologous adoptive immunotherapy.

Typical adoptive immunotherapy involves the administration of immunologically active cells to an individual for the purpose of providing a beneficial immunological effect such as reduction or control of cancer. The immunologically active cells are typically taken by venipuncture or leukophoresis either from the individual to be treated, termed autologous treatment, or

from another individual, termed an allogeneic treatment. The lymphocytes are then cultured to increase their number and to activate their antitumor activity, and then infused back into the patient. Thus, the majority of conventional efforts in adoptive immunotherapy are directed at expanding cell numbers *in vitro* followed by infusion back into the patient.

Animal experiments involving the transfer of immunologically active cells from healthy animals to animals with cancerous tumors have indicated that adoptive immunotherapy can elicit an antitumor effect in certain tumor models with a high degree of effectiveness. The administration of IL-2 together with LAK cells has proven effective in the treatment of a variety of murine malignancies. The transferred LAK cells also proliferate *in vivo* as a result of IL-2 treatment. Human clinical trials have demonstrated that LAK cells plus IL-2 or IL-2 alone can be effective in mediating the regression of established metastatic cancer in selected patients. S.A. Rosenberg, "Immunotherapy of Patients with Advanced Cancer Using Interleukin-2 Alone or in Combination With Lymphokine Activated Killer Cells," in *Important Advances in Oncology* 1988: J.B. Lippincott Co., 217, (1988).

However, the success of adoptive immunotherapy has been limited by the large number of cells required in the therapy, the large amount of culture medium and large number of hours involved in culturing cells to develop LAK activity, the length of time sufficient LAK activity must be maintained for the desired therapeutic efficacy,



the time involved in clinical treatment and the side effects of treatment. Improvements in the *in vitro* culturing process have been sought in order to increase the efficacy of adoptive immunotherapy. Cells cultured  
5 in IL-2 and/or monoclonal antibodies against the antigen receptor complex CD3 (anti-CD3 MAb) have been found to induce proliferation of a greater number of T cells, which demonstrate an increased anti-tumor activity. P.M. Anderson et al. *Cancer Immunol. Immunother.*, 27: 82  
10 (1988); P.M. Anderson et al., *J. Immunol.*, 142: 1383 (1989); and A.C. Ochoa et al., *Cancer Res.*, 49: 963 (1989).

Adoptive immunotherapy of renal adenocarcinoma in the murine RENCA model using IL-2-activated killer cells in  
15 conjunction with chemotherapy showed some success in reducing tumors, but the effect was suspected to be cytokine mediated. Wiltout, *Progress in Neuro Endocrin Immunology*, 4:154 (1991).

There has been limited success with efforts to  
20 activate *in vivo* antitumor mechanisms. Only a minority of patients receiving high doses of IL-2 experienced therapeutic effects, and significant toxicity is observed. The direct infusion of anti-CD3 monoclonal antibody alone inhibits nonspecific antitumor function in  
25 mice. D.W. Hoskin et al., *Cancer Immunol Immunother.*, 29: 226 (1989). Based on the positive results in murine models, direct infusion of anti-CD3 has been attempted in humans. Although patients who have directly received the anti-CD3 MAb designated OKT3 have experienced the

activation of some T cells *in vivo*, the toxicity of intravenous OKT3 reaches the maximum tolerated dose (MTD) at low doses before it starts showing some immune efficacy. W. Urba et al., Cancer Res., March 1991. It is believed that the free OKT3 is responsible for the majority of these toxic effects.

Due to inadequacies of treatment with single modalities, synergism has been sought. Flavone acetic acid (FAA) is a cytokine-inducing synthetic drug which showed a synergistic therapeutic effect with IL-2 in reducing RENCA murine tumors. Antitumor effects of flavonoids, a cytokine inducer, in combination with IL-2 are therefore promising. FAA is a biological response modifier (BRM) which has been shown to augment systemic natural killer (NK) cell activity and to synergize with IL-2 for the successful treatment of advanced RENCA. Wilttrout et al., *J. Immunol.*, 140: 3261 (1988); U.S. Patent No. 5,096,707 and 5,061,488. Cytokines (TNF,  $\alpha$ -IFN, and  $\gamma$ -IFN) induced by FAA have been implicated in the therapeutic synergy with rIL-2. CD8<sup>+</sup>-T-lymphocytes are critical in mediating this synergistic effect. FAA induces cytokine genes *in vitro*. In this model, immunosuppressive T-cells are induced during the progression of the RENCA tumor. Gregarian et al., *Cancer Immunol Immunother* 31: 325, 31:335 (1990).

T lymphocytes from hosts bearing tumors exhibit decreased immune function in a variety of *in vitro* tests. R. Lafreniere et al., *J. Surg. Oncol.*, 43: 8 (1990); R.J. North et al., *J. Exp. Med.*, 159: 1295 (1984); M.

Sarzotti et al, *Int. J. Cancer*, 39: 118 (1987). It has been observed that before the decrease in the immune responsiveness in peripheral blood lymphocytes, T lymphocytes infiltrating a tumor exhibit poor cytotoxic activity against autologous or allogeneic tumor cells. E.F. Klein et al., 1980, In: *Contemporary Topics in Immunobiology*, I.P. Witz and M.G. Hanna, Jr., eds. Plenum Press, N.Y., p 79-107; B.M. Vose et al., *J. Cancer*, 44: 846 (1981).

10       The molecular basis of the decreased immune responsiveness of the T cells derived from tumor-bearing hosts is poorly understood. It has been proposed that decreased immune responsiveness of the T cells is caused by the development of suppressor lymphocytes. S.B. Mizel et al., *Proc. Natl. Acad. Sci. USA*, 77: 2205 (1980); C.C. Ting et al., *Int. J. Cancer*, 24: 644 (1979). Another proposal is that responsive T cell clones are deleted. S. Webb et al., *Cell*, 63: 1249 (1990). It has also been proposed that decreased immune responsiveness of the T cells is the result of the induction of T cell anergy. M.K. Jenkins et al., *J. Exp. Med.*, 165: 302 (1987). Others have suggested that the major alteration in the immune response is produced by a modification in the presentation of the antigen which results in an inadequate response of the CD4<sup>+</sup> helper T lymphocytes. These data have been strengthened by the observation that tumor cells transfected with cytokine genes induce a protective antitumor response, and result in an

immunological memory response. E.R. Fearon *et al.*, *Cell*, 60: 397 (1990).

In an *in vivo* tumor model, the progressive growth (>26 days) of a subcutaneous implant of murine colon carcinoma designated MCA-38 resulted in decreased lytic function by the CD8<sup>+</sup> T lymphocytes, a decrease which was associated with decreased expression of mRNA for tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) and granzyme B, and the complete loss of the ability of adoptively transferred cells to mediate an antitumor effect *in vivo* (Loeffler *et al.* 1992, *J. Immunol.* 149 :949). However, proliferation, lymphokine production, and lymphokine receptor upregulation in CD4<sup>+</sup> T cells were comparable in normal and tumor-bearing mice. Cells with suppressor function were not detected, nor was the production of transforming growth factor- $\beta$  (TGF-B) detected in the lymphocytes from tumor-bearing mice or the MCA-38 tumor cells.

Augmentation of the immune response in immune compromised patients via infusions of lymphokines and/or adoptive immunotherapy has met with variable and limited success. Methods are needed to improve this type of treatment. A need exists for effective methods of measuring the progression of immunosuppression so that attempts at augmenting the immune system in an immunosuppressed patient can be effectively timed. A need also exists for a method by which a patient's level of immunosuppression is estimated and used to accurately predict the likelihood of a patient's response to therapy. The patient's therapy can then be developed in

a systematic fashion. A method is needed by which a clinician can determine whether a patient's T lymphocytes will be capable of activation and, thus, whether autologous adoptive immunotherapy will likely be efficacious.

A need exists for a method by which the immunosuppressed state of T lymphocytes during disease progression can be circumvented or reversed so that the T cell immune response in the patient can develop or be augmented. A need also continues to exist for a method of screening for immunosuppressive agents and agents that reverse or inhibit immunosuppression.

There is a need to detect the presence of tumors, in particular early in the development of a tumor, so that treatment effectiveness is enhanced. Also, improved methods for staging of the disease would facilitate choice of the most appropriate treatment modalities. There is also a need to test the effectiveness of treatment modalities prior to clinical trials, and as adjuncts to clinical trials.

The present invention addresses limitations in the art for the detection, monitoring, and reversal of immunosuppression, and of diseases generally characterized by immunosuppression, for example, cancer.

25

#### SUMMARY OF THE INVENTION

The present invention relates in part to identification of a soluble immunosuppressive factor which is capable of effecting a change in the level of expression of various proteins involved in the TCR

subunits, in the T lymphocyte signal transduction pathway, and in the NF- $\kappa$ B/rel proteins. Pattern of expression includes presence or absence of the protein in the cell or in one or more subcellar structures, including reduced presence, as well as alterations in protein structures, including truncation.

By "factor" is meant a composition that is present in the serum derived from an immunosuppressed mammal and is capable of altering the expression of the TCR related proteins. The factor is present in the supernatant of some tumor cell cultures. The term "factor" includes any subcomponent that is isolated and purified from said serum or supernatant, and has the immunosuppressive and TCR protein altering properties described herein. The change in the pattern of protein expression may occur in one or more proteins that compromise the TCR receptor, the T lymphocyte signal transduction pathway, and the NF- $\kappa$ B/rel proteins.

The level of expression of specific proteins that comprise the TCR receptor and specific proteins in the signal transduction pathway, is generally decreased in immunosuppressed mammals as compared with the level characteristic for the proteins in a preparation of cells derived from a non-immunosuppressed mammal, or from a culture of cells which originated from a non-immunosuppressed mammal, or a culture of cells characterized by a protein level characteristic of a non-immunosuppressed mammal. However, because expression of the proteins that are an aspect of the present invention

are part of an inter-related and complex immunological system, a perturbation in one protein of the system may effect other protein levels in different ways, that is, may either increase or decrease them at a particular point in time.

What is important is that if at least one protein level in the immunological system is decreased to a level which disrupts the operation of the system, the system becomes suppressed, that is, unable to operate as is necessary to perform the immunological functions characteristic of a healthy mammal. The degree of suppression varies, and is generally associated with more severe clinical problems as suppression becomes more pronounced. Also, as immunosuppression progresses, more protein levels tend to show changes. As an indicator of the progression of immunosuppression, the level of a particular protein decreases correspondingly, and a plurality of proteins of the present invention show alterations from the non-immunosuppressed state.

Generally the protein levels decrease, although some levels increase. For example, as CD3  $\zeta$  decreases, FC $\epsilon$  $\gamma$  increases.

An embodiment of a protein which decreases in the presence of the immunosuppressive factor of the present invention is a protein subunit of TCR. These proteins include CD3 $\zeta$  and CD3 $\gamma$ .

An embodiment of a protein which increases as the CD3 $\zeta$  level decreases, that is, whose expression is inversely correlated with the expression of this protein,

is Fc $\epsilon$  $\gamma$ , a protein related to the IgE receptor. Control of the Fc $\epsilon$  $\gamma$  protein by methods of the present invention may represent a way to control an allergic response because the methods of the present invention are useful  
5 for screening for increased Fc $\epsilon$  $\gamma$  and for selecting agents to inhibit that increase.

Another embodiment of a protein which decreases in the presence of the immunosuppressive factor is a signal transduction pathway protein. This protein includes a  
10 tyrosine kinase such as those of the Src family, notably Fyn and lck, as well as proteins PLC $\gamma$  and GAP.

The pattern of TCR subunit proteins, signal transduction pathway proteins, or protein transcription factors in the NF- $\kappa$ B/rel system is altered in the  
15 presence of tumors, a condition associated with the immuno-suppressive state. A pattern in this context refers to the presence or absence of different protein components which are found in the non-immunosuppressed state in non-tumor bearing mammals, and to the presence  
20 or absence of various related components characterized by physical properties such as molecular weight which are different from the properties in the nonimmunosuppressed, non-tumor bearing, state. The presence or absence of the NF- $\kappa$ B/rel factors, and their physical properties such as  
25 molecular weight, are determined by methods known to those of skill in the art. These methods include Western blot analysis, gel shift analysis, and UV- crosslinking analysis. Nuclear extracts are analyzed. If lymphocyte



preparations are used for the assay, for example from a spleen, short term cultures are preferred.

Other properties of the soluble immunosuppressive factor of the present invention include its presence in the serum of mammals that have tumors present. It also appears in the supernatant of cultures of some tumor cells.

It was found that supernatants of some cultured tumor cells suppressed the *in vitro* cytolytic activity of normal lymphocytes. Embodiments of said cultures include MCA-38 and MBL-2. The factor may, therefore, be isolated and purified from preparations of mammalian cells derived from tumor-bearing sources. The factor is recoverable after a certain period of time that the tumor has been present in the mammal. The longer the tumor is present, the more likely is the factor to be recoverable. It is understood that there may be one or more tumors. The period after which the factor is recoverable varies with the type of mammal, the type of tumor, and other factors related to the malignant state. For example, the soluble factor is recoverable from mice that have tumors present for at least about 26 days in the tumor lines disclosed herein.

The soluble factor is recoverable from biological specimens that include mammalian serum. The factor is also recoverable from the supernatant of some cultured cells, for example, cells cultured from the MCA-38 line or from the MBL-2 lymphoma line. These lines are available for use as described herein.

A general method for determining the level of immunosuppression in a mammal, includes the steps of determining the level of expression, in a mammalian lymphocyte preparation, of at least one selected TCR subunit protein or protein in the T lymphocyte signal transduction pathway; and comparing the level of protein expression with the characteristic level of expression of the selected protein found in healthy, that is, non-immunosuppressed, individuals of the same mammalian species. The TCR subunit proteins that are suitable for the practice of the present invention include CD3 $\zeta$  or CD3 $\gamma$ . The proteins in the signal transduction pathway that are suitable for the practice of the present invention include tyrosine kinases of the src family p56<sup>lck</sup> and p59<sup>fyn</sup>, and the proteins PLC $\gamma$  and GAP.

Embodiments of changes in levels of protein expression which are directly associated with progression from the normal to the malignant state include: T cell antigen receptors (TCR) that show decreases in CD3 $\gamma$  and a complete lack of a CD3 $\zeta$  chain. The latter chain is replaced by an Fc $\epsilon$  $\gamma$ -chain.

Embodiments of changes in the levels of expression of proteins in the lymphocyte signal transduction pathway that are associated with progression from the normal to the malignant state included reduced expression of tyrosine kinases. In an illustrative embodiment, p56<sup>lck</sup>, p59<sup>fyn</sup>, PLC $\gamma$  and GAP are reduced compared to normal levels. In any one individual, one or more protein levels may be changed. As malignancy progresses, generally, more

protein levels are changed. The sequence of appearance of the changes may vary with different diseases.

Changes discovered herein are observed both in tumor-bearing mice and humans when compared to non-tumor-bearing animals or humans. At least one change from normal TCR complex protein expression level is observed, although generally there is a correlated response, that is, a pattern associated with the advancing malignant state.

Another assay for the immunosuppressed or tumor-bearing state is the pattern of the transcription factors of the NF- $\kappa$ B/rel family. The proteins of interest include c-rel, p65 and p50. In some abnormal conditions, all three proteins are absent. In other conditions, only one or two are absent. In still other abnormal conditions, new forms of protein replace a form present in the normal state. Comparisons are preferably made between comparable cell samples from a mammalian species. For example, in the presence of a RENCA tumor in a mouse, p50, a component of nuclei of a T lymphocyte preparation from a non-tumor bearing mammal, disappears, and is replaced by p48 and p44 ( proteins with estimated molecular weights of 48 and 44 kD respectively as determined by Western blots.) Some of the new protein forms appear to be related to the larger molecular weight form they replace, by N-terminal truncation of the larger form.

Cancer patients are staged or evaluated based on expression levels and patterns of proteins affected by immunosuppression. The likelihood of success of such

immunotherapy is predicted by the results of staging and evaluation. The protein levels of the TCR subunits and signal transduction pathway, and the pattern of the NF- $\kappa$ B/rel proteins, are informative for these purposes. In  
5 vitro responses of cells to therapies may be predictive of either the efficacy of the treatment, or the immunological strength of the cells, or a correlate thereof.

An aspect of the present invention is that it  
10 provides a method of identifying a patient having T lymphocytes capable of activation for autologous adoptive immunotherapy by assaying for changes in TCR receptor, signal transduction, or NF- $\kappa$ B/rel proteins. This method includes the steps of determining, in a lymphocyte  
15 preparation from a patient being evaluated for immunosuppression, the level of expression of at least one selected TCR subunit protein or of a protein in the T lymphocyte signal transduction pathway, or the pattern of at least one of the NF- $\kappa$ B/rel proteins.

20 A method for quantitating the level of expression of the proteins of the present invention is the expression ratio, although other comparable methods are within the scope of this invention. An expression ratio is the ratio of the number of T lymphocytes expressing the  
25 selected protein to the total number of T lymphocytes counted. The level of protein expression is compared with the normal level of expression of the selected protein found in healthy, that is, non-immunosuppressed individuals. Another method for quantitating an

expression level of a protein of the present invention is to express the amount (proportion) of the protein present in an amount of total protein isolated from a biological specimen, e.g. T-lymphocytes.

5           For the pattern of transcription factors of the NF- $\kappa$ B/rel family, presence or absence of molecular weight components are determined in nuclear extracts. At least one component is assayed, although preferably a plurality are assayed, because different abnormal states are  
10 characterized by different patterns.

A threshold is defined as a level which is the minimum level of a protein which is compatible with lymphocyte stimulation. A threshold may also be defined as a pattern of NF- $\kappa$ B/rel proteins that is compatible  
15 with lymphocyte stimulation. Compatibility is determined as that level of stimulation effected by agents such as anti-CD3 that is generally required for clinical improvement, in therapies involving lymphocyte transfusions. Alternatively, a threshold level is  
20 defined as a protein level and/or pattern that does not interfere with the immunological response.

Application of the methods of the present invention to the treatment of patients having a disease responsive to immunotherapy, permits selection of patients whose  
25 lymphocytes are likely to respond to stimulation, and for whom immunotherapy is likely to succeed. Patients whose level of expression of a selected protein or proteins, and/or pattern of proteins, is not below the threshold

level for response to lymphocyte stimulation, are likely candidates for immunotherapy.

Another aspect of the present invention relates to a method of selecting agents which cause immunosuppression of mammalian T lymphocytes. The method includes the steps of: providing a mammalian T lymphocyte preparation wherein the level of expression of at least one selected TCR subunit protein or protein in the signal transduction pathway, and/or pattern of NF- $\kappa$ B/rel proteins, is characteristic of healthy, that is, non-immunosuppressed, individuals of the same mammalian species; culturing the lymphocyte preparation in the presence of an agent suspected of causing immunosuppression; determining the level of expression and/or pattern of the selected protein; and selecting an agent which causes a significant reduction below normal in the level of expression of the selected protein, or a pattern change from normal, wherein normal is defined as a threshold level determined to represent the non-immunosuppressed state. This process is conducted *in vivo* after the administration of a potentially immunosuppressive drug. A method of inducing immunosuppression, for example, in conjunction with organ transplantation, is to administer the soluble immunosuppressive factor of the present invention to a patient.

Similarly, a method of identifying an agent which reverses immunosuppression of mammalian T lymphocytes, includes the steps of: providing a mammalian T lymphocyte preparation from an immunosuppressed mammal, wherein the

level of expression of at least one selected TCR subunit protein or protein in the signal transduction pathway is below that threshold level characteristic of healthy i.e. non-immunosuppressed individuals of the same mammalian species, or exhibits an altered pattern of NF- $\kappa$ B/rel proteins, or some combination of either type of changes; culturing the lymphocyte preparation in the presence of an agent suspected of reversing immunosuppression; determining the level of expression of the selected protein; and selecting for an agent which causes a significant increase in the level of expression of the selected protein. This process is conducted *in vivo* after the administration of a drug that potentially reverses immunosuppression.

Using the methods of the present invention to detect changes in proteins of the TCR subunits, the signal transduction pathways, or the NF- $\kappa$ B/rel proteins, treatments to reduce or eliminate tumors, may be evaluated. For this evaluation, levels of the proteins are determined in a tumor bearing mammal prior to administering the treatment. Following treatment, the levels or patterns or both, of the same proteins are determined and compared to pre-treatment levels to determine whether changes have occurred. Generally, statistically significant differences are required to decide that changes have occurred. Comparisons may also be made to protein levels of comparable non-tumor-bearing mammals for further evaluations of treatment efficacy.

In an illustrative embodiment, mammals bearing established tumors are treated with a combination of a flavonoid which is a cytokine-inducer, in conjunction with IL-2. Evaluation of alternations in the tyrosine phosphorylation pattern indicates that reduced levels of p56<sup>lck</sup>, p59<sup>fyn</sup> PLC $\gamma$ 1 and the zeta chain of the CD3-complex associated with presence of a tumor, are reversed after said treatment in mice that also show tumor reduction. In tumor-bearing mice, c-rel and p65 of the NF- $\kappa$ B/rel family were absent, and p48 and p44 appeared in place of p50. After treatment, this pattern returned to approximately a normal state. An interpretation of these results is that the flavonoid, cytokine, IL-2 combination, acts against tumors by restoring the components required for normal immunological functioning, for example, signal transduction pathways, thereby allowing the T-cells to mount an effective anti-tumor response.

Embodiments of agents that induce re-expression of the CD3 $\zeta$  protein after its level has been decreased in tumor-bearing mammals, include: ionomycin; ionomycin in combination with any of the following: phorbol miristic acetate, IL-2, PMA and IL-2, anti-CD3 and IL-2; and the monoclonal antibody, anti-CD3.

A screening method for an agent that inhibits the immunosuppressive factor of the present invention is performed by determining the immunosuppression level of a system to which the agent has been added, and comparing the level to the immunosuppression levels before adding



the agent. An illustrative embodiment includes the following steps:

1. developing a monoclonal antibody to the agent so that a complex will be formed when the antibody is added to a preparation containing the agent, thereby inhibiting the action of the agent; the antigen-antibody complex is labelled by methods known to those of skill in the art to detect its formation, thereby leading to the inference that the agent is present in a preparation;
2. adding the agent to be tested to a first cellular system that contains the immunosuppressive factor;
3. adding both the agent and the antibody directed to the agent, to a second cellular system that also contains the immunosuppressive factor;
4. determining the level of immunosuppression using the assays of the present invention to determine protein expression levels, for example of the TCR subunits and the signal transduction pathway, and/or the pattern of the NF- $\kappa$ B/rel proteins;
5. comparing the immunosuppression levels of the first cellular system with that of the second to determine whether the monoclonal-antibody containing system exhibits a reversal of immunosuppression; this reversal is indicated by the protein levels and/or patterns of the second cellular system being above the levels of the first cellular system, and preferably, the levels or patterns being consistent with levels or patterns characteristic of the non-immunosuppressed state

of a comparable cellular system; a comparable cellular system includes a system derived from the same mammalian species, the same cell type, and having other immunologically related properties that are similar.

5        This invention also relates to an agent identified by the methods of the present invention as inhibiting the immunosuppressive factor, that is, preventing or reversing immunosuppression effected by a malignant state or other abnormal conditions which induce immuno-  
10        suppression.        Immunosuppression caused by chemical modalities are included in this definition.

      An antibody directed to the immunosuppressive factor is also within the scope of the present invention. The antibody is prepared by employing an isolated and  
15        purified epitope of the isolated immunosuppressive factor of the present invention by methods known to those of skill in the art for preparing polyclonal and monoclonal antibodies.

      An immunosuppressive factor is isolated and purified  
20        from serum of tumor-bearing mammals, from cells that are derived from tumors or tumor-bearing mammals, or from other biological sources that effect immunosuppression when applied to non-immunosuppressed systems. In an illustrative embodiment, the factor is a soluble  
25        proteinaceous compound. Using the isolated and purified factor, the gene or genes encoding the immunosuppressive factor are cloned and the nucleotide coding sequences determined.

A gene encoding the immunosuppressive factor of the present invention is cloned by methods known to those of skill in the art. The factor, or at least the segment necessary for immunosuppression, may be purified by use  
5 of a monoclonal antibody directed against the factor or epitopic segments thereof or by standard biochemical purification. The amino acid sequence is determined for the purified factor and degenerate oligonucleotides are prepared and used to screen a library of nucleotide  
10 sequences.

An antisense construct directed against the expression of the immunosuppressive factor of the present invention is useful for inhibiting the action of the factor. Administration of the antisense construct to a  
15 mammal is used to inhibit progression toward the immunosuppressive state. The antisense construct is generally transfected into cells, and the cells administered to a mammal.

Mammalian cells may be transfected with the gene for  
20 the soluble factor using methods known to those of skill in the art.

An aspect of the present invention is a vaccine which is prepared from at least an immunologically active portion of the soluble immunosuppressive factor of the  
25 present invention. The vaccine is prepared by methods known to those of skill in the art.

A kit for determining the level of immunosuppression includes an antibody directed to a protein from a group including a TCR subunit, a signal transduction pathway,

and a NF- $\kappa$ B/rel family. In separate containers, one or more antibodies are present, each directed to an individual protein of the present invention, also included in the kit are means for detecting the formation of an antigen-antibody complex, from which the presence of a particular protein is inferred. An antibody specific for the sequence that differs in an abnormal compared to a normal state, is useful for detecting degraded proteins.

10       A kit for determining effectiveness of therapeutic agents for reversing immunosuppression and tumor progression, includes several lymphocyte preparations each in a separate container. A first preparation is provided for control levels and patterns. This is  
15       generally a lymphocyte preparation from a spleen of a non-immunocompromised, non-tumor-bearing mammal of the same species as the mammal for which the therapy is directed. A second preparation of comparable cells and mammalian source is from an immunosuppressed or tumor-  
20       bearing mammal. Generally, the cells are required to be frozen in liquid nitrogen upon receipt of the kit, until the kit is to be used. The preparations will either be nuclear extracts, or the kit will include lysing means to provide nuclei for the analysis of the NF- $\kappa$ B/rel  
25       patterns. The efficacy of the potential therapeutic agent is determined by adding the agent to the second preparation, and comparing protein levels and/or patterns by methods known to those of skill in the art, after an appropriate interval. The appropriate interval is

determined for a particular cell type, and protein assay.

Mammalian cells treated with an agent that inhibits the immunosuppressive factor, and mammalian cells treated with the immunosuppressive factor, are useful therapeutically for either decreasing or increasing immunosuppression, depending on the nature of the disease or condition to be treated. The treated cells may be used for adoptive immunotherapy.

An immunosuppressed mammal is treated by administering a therapeutically effective amount of an agent identified by the methods of the present invention as capable of reversing immunosuppression, in a pharmaceutically acceptable diluent. Therapeutically effective amounts are determined empirically for a particular disease or condition. The treated mammal includes a human.

Further objects, features and advantages of the invention will become apparent from the detailed description of the invention which follows, in which various terms used are defined as follows:

T lymphocytes or T cells include all subsets of lymphocytes which carry the T cell antigen receptor. These subsets include lymphocytes which are  $CD3^+CD4^+(\alpha\beta^+)$ ;  $CD3^+CD8^+(\alpha\beta^+)$ ;  $CD3^+CD4^-CD8^-(\gamma\delta^+)$ ; and  $CD3^+CD56^+$ .

Immunotherapy includes adoptive immunotherapy which includes cellular adoptive immunotherapy which involves the administration of immunologically active (immunocompetent) cells to an individual for the purpose

of providing a beneficial immunological effect to the individual, such as reduction or control of cancerous or diseased tissue.

As used herein, immunotherapeutic activity or immune response or immunologically active or immunocompetent includes anti-tumor activity, anti-infected cell activity, anti-disease agent activity and killer activity of white blood cells.

Culturing indicates the process whereby T cells are placed in a tissue culture medium (TCM) comprising all the nutrients required for growth. Stimulating indicates culturing the T cells in a TCM supplemented with one or more cytokines, or alternatively, with one or more T cell anti-surface receptor antibodies, with or without one or more cytokines. The process can take place in any vessel or apparatus suitable for cell or tissue culture. The process can involve various stages of culturing and subculturing. However, typically only one stimulating step is desirable.

The signal transduction pathway includes any protein, the expression of which is induced, linked or regulated by the binding of a ligand or an antibody to any T cell surface receptor. These proteins include, but are not limited to, Jun, Fos, Myc, GAP, Raf1, c-rel, NF- $\kappa$ B, Plc $\gamma$ , Protein G, Inositol Phosphate, Protein Kinase C, Map1-kinase, CD45 phosphatase and the Src family of kinases including Lck, Fyn, Yes and Lyn.

Antibody includes any protein or protein analogue which binds specifically to an appropriate epitope of the

T cell receptor that is stimulatory. Antibody also includes any protein or protein analogue which binds specifically to a TCR subunit protein,  $Fc\epsilon\gamma$ , or a protein in the T lymphocyte signal transduction pathway. The term includes antibodies made by conventional methods including polyclonals, monoclonals or fragments thereof, as well as genetically engineered or synthetic molecules, e.g., single chain antibodies, that contain a binding region that is the functional equivalent of an antibody in its binding specificity.

Cytokine includes those proteins which mediate much of the intercellular signalling required for an integrated response to a variety of external stimuli. Cytokines are potent mediators which interact with specific high affinity receptors on the cell surface. Cytokines have been shown to affect the function of all cell types involved in an immune response; to be involved in lymphopoiesis and hemopoiesis; and have been implicated in the pathophysiology of a large number of diseases. Lymphokines are the preferred cytokines in the claimed invention.

NF- $\kappa$ B transcription activator is a multiprotein complex which activates gene transcription. Three protein subunits, I $\kappa$ B, p50 and p65 control the biological functions of NF- $\kappa$ B. Rel proteins are transcriptional activators, are capable of forming heterodimers with p50, and are sequence specific DNA binding proteins which are capable of recognizing  $\kappa$ B motifs.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the results of an experiment in which mice were treated with T-AK cells derived from three groups of mice: (1) non-tumor-bearing mice (normal), (2) mice bearing a tumor for <21 days (early TBM); (3) mice bearing a tumor for >30 days (late TBM). Liver metastases were counted 12 days after tumor inoculation. Groups were compared using Student's unpaired t test. \*indicates a  $P < 0.001$ , treated versus control; Bars show the S.D. (standard deviation).

FIG. 2 illustrates (A) the cytolytic activity of normal, early and late TBM T-AK cells against MCA-38 (colon carcinoma); (B) the cytolytic activity of normal, early and late TBM T-AK cells against MBL2 (lymphoma); and (C) the cytolytic activity of normal, early and late TBM, T-AK cells against RENCA (renal cell carcinoma) tumor cell lines. Enriched T cells were activated with anti-CD3 and cultured in tissue culture medium (TCM) containing 100 U recombinant interleukin-2/ml (rIL-2/ml). Lytic function was tested on day 2 of culture.

FIG. 3 illustrates the cytolytic activity of normal, early and late TBM T-AK cells against MBL2. Enriched T cells were activated with anti-CD3 and cultured in TCM containing 100 U rIL-2/ml. Lytic activity was tested on days 2, 4 and 7 of culture in a 4-hr chromium release assay.

FIG. 4. Surface expression of the TCR-CD3 complex measured by flow cytometry. Isolated T cells from normal and tumor-bearing mice (dotted and dashed lines



respectively) were incubated with control fluorescein-labeled IgG<sub>2A</sub> and (A) antibody to mouse TCR $\alpha\beta$  (clone H57-597 Pharmingen) or (B) anti-CD3 $\epsilon$  (145-2C11). Normal mice (shaded); tumor-bearing mice (unshaded).

5

#### DESCRIPTION OF THE PREFERRED EMBODIMENT

T-lymphocytes from tumor-bearing mice (TBM) in particular those having tumors for a long period of time, show alterations in the characteristics of the TCR related proteins. Cancer patients show similar alterations. These observations suggest that proliferation of tumors relate to break-down in operation of proteins of the TCR subunits, the signal transduction pathways, and the NF- $\kappa$ B/rel system. Conversely, successful anti-tumor therapy correlates with reversal of alterations in these proteins, for example, reversal from the lack of, or diminished expression of, these proteins, to their presence at normal levels.

15

These observations provided the basis for developing assays for immunosuppression in mammals. The assays are based on changes in the TCR subunit proteins, in proteins of the signal transduction pathway, and in the NF- $\kappa$ B/rel system. Clinical uses for these assays are numerous.

20

A soluble immunosuppressive factor present in tumor bearing mammals was identified by its effect on the TCR related proteins of the present invention and by its association with progressive immunosuppression.

25

The methods of the present invention are suitable for the evaluation of treatments, and to methods of treatments of a great variety of diseases characterized

by the malfunctioning of the immune system. Such diseases include those that result in progressive immunosuppression as well as diseases in which "self" is recognized as foreign and therefore, an autoimmune response is established.

Diseases which result in progressive immunosuppression include cancers of many different tissues including leukemia, Hodgkin's disease, lung cancer, colon cancer, gliomas, renal cell carcinoma, and the like. Progressive immunosuppression is observed in a great variety of infections including those that are intracellular such as leprosy, tuberculosis, leishmania; those that are extracellular such as sepsis, diseases of viral etiology such as those caused by HIV, cytomegalovirus, Epstein Barr, and the like; parasitic infections such as schistosomiasis, malaria, and the like.

Diseases which result in the establishment of an autoimmune response include lupus, autoimmune thyroiditis, scleroderma, rheumatoid diseases such as rheumatoid arthritis, and the like.

Organ transplantation requires induction of immunosuppression. The soluble factor of the present invention is useful to achieve this state. The assays of the present invention are used to evaluate immunosuppressive agents.

Treatment modalities are developed from identification of immunosuppressive agents or agents that reverse immunosuppression, by assays of the present

invention. Treatments include direct administration of immunological stimulants to a mammal having cancer or another disease impairing the immune system, or use of adoptive immunotherapy.

5 A method of delivery of effective immunotherapeutic agents are liposomes. Effective immunotherapeutic agents include those that restore levels of TCR subunits and signal transduction proteins, to levels prior to the appearance of tumors, or prior to induction of the  
10 diseased state. Effective immunotherapeutic agents include those that restore the transcriptional factors of the NF- $\kappa$ B/rel family to their prediseased state.

**Characteristics of T-Lymphocytes from (TBM)  
Tumor-Bearing Mice**

15 1. **Decrease in Therapeutic Efficacy**

There was a marked decrease in the therapeutic efficacy of adoptively transferred T lymphocytes from murine hosts bearing a tumor for > 26 days (These hosts are referred to as late tumor-bearing mice or late TBM)  
20 as distinguished from normal mice and mice bearing a tumor for < 21 days (early tumor-bearing mice or early TBM).

*In vitro* analysis of the functions of the T lymphocytes from late TBM showed an apparently normal  
25 proliferative response to anti-CD3 and IL-2 and adequate lymphokine production from CD4<sup>+</sup> cells. However, a significant decrease in the cytotoxic function of CD8<sup>+</sup> cells, was observed. The decreased cytotoxicity was not due to cell-mediated suppression. The expression of

genes encoding for lytic molecules such as TNF $\alpha$  and granzyme B was significantly decreased.

Expression of the CD3 $\zeta$  and CD3 $\gamma$  chains was not detectable in T lymphocytes from late TBM. The  $\zeta$  chain  
5 was replaced by the expression of the Fc $\epsilon$  $\gamma$  chain, a member of the  $\zeta$  family of chains. Lymphocytes from TBM also exhibited a marked decrease in the Lck and Fyn proteins. These changes were paralleled by a decreased ability to mobilize Ca<sup>2+</sup> and in an altered pattern of  
10 tyrosine phosphorylation.

CD8<sup>+</sup> T lymphocytes in tumor-bearing mice have impaired lytic and therapeutic function (Loeffler et al., 1992) and alterations in the expression and function of signalling molecules. CD3 $\zeta$ -chain is not only a critical  
15 signal transducing component of the TCR (Romeo and Seed, Cell 64, 1037, 1991), but also the limiting subunit in the assembly and membrane expression of the TCR-CD3 complex in T cell hybridomas. Weissman et al., Science 239: 1018, 1988). Lytic function is reduced in cells  
20 lacking the TCR- $\alpha$ -chain or the CD3- $\delta$ -chain. Schmitt, Verhuisi et al., Nature 325: 628 (1987). The effect of the absence of either CD3 $\zeta$  or CD3 $\gamma$  from T cells in tumor-bearing mice is not clear.

A subpopulation of large granular T-lymphocytes  
25 (LGLs) characterized as CD3<sup>+</sup>, NK1.1<sup>+</sup>, CD16<sup>+</sup>, CD4<sup>-</sup>, and CD8<sup>-</sup> and expressing the Fc $\epsilon$  $\gamma$ -chain instead of the  $\zeta$ -chain has been described (Koyasu, J. Exp. Med. 175: 203, 1992). These lymphocytes differ phenotypically from those seen in tumor-bearing mice. However, these LGLs do have lytic

function. Thus, target cell lysis is not dependent on the presence of the CD3 $\zeta$ -chain. Moreover, chimeric molecules made with Fc $\epsilon\gamma$  expressed in cytotoxic T cell lines maintain their lytic function. This suggests that Fc $\epsilon\gamma$  and  $\zeta$  may be interchangeable in coupling to lytic mechanisms, especially in view of the degree of homology between these two chains (Romeo et al., Cell 68:, 899 (1992)).

2. Decreased Expression of PLC  $\gamma$  and GAP in Tumor Bearing Mammals

Experimental data using a Western blot technique and using the antibody against PLC- $\gamma$  (Upstate Biotechnologies Inc., Lake Placid, N.Y., 1:5000 dilution) and anti-GAP (same company, at 1:2000 dilution) has demonstrated a decreased expression of both antigens in tumor-bearing mice. Testing of these signal transduction mediators in cancer patients has shown a decrease in PLC- $\gamma$ , but not always in GAP.

3. Decreased Kinase Function in Tumor Bearing Mice (TBM)

Testing of the kinase function (ability to phosphorylate) of Lck and fyn has demonstrated a decrease in kinase function in both of these in tumor-bearing mice.

Characteristics of T Lymphocytes and Protein Expression Levels in Cancer Patients

Similarly, the expression of CD3 $\zeta$  protein in some human cancer patients was undetectable or markedly reduced compared to healthy i.e., not tumor-bearing, controls. The expression of CD3 $\zeta$  protein was analyzed by Western blot in human cancer patients. For example,

equal numbers of cells or equal amounts of proteins isolated from the lymphocytes isolated from the peripheral blood of two patients with renal cell carcinoma, one patient with liver metastases of an ocular melanoma, and a healthy individual, were analyzed using anti-CD3 $\zeta$  rabbit serum. Expression of CD3 $\zeta$  protein was detected in the healthy control. In contrast, the expression of CD3 $\zeta$  was undetectable in the sample taken from one patient with renal carcinoma and from a patient with liver metastases of an ocular melanoma. The expression of CD3 $\zeta$  protein was reduced by 95% in a second patient with renal cell carcinoma. The cancer in each of these patients was present for greater than 30 days.

Progression of cancer leads to immunosuppression of T lymphocytes. Loss in the antitumor effects of T cells in adoptive immunotherapy is correlated with a significant decrease in the cytotoxic function of CD8<sup>+</sup> cells and changes in protein expression.

Data obtained from cancer patients including those with melanoma, renal cell carcinoma, acute lymphocytic leukemia, and multiple myeloma has shown that some patients present a marked decrease in the expression of the CD3 $\zeta$  chain as determined by use of anti- $\zeta$  antiserum 387 (obtained from Dr. Alan Weissman, NCI). In addition decreases in Fyn (UBI), Lck (UBI), and PLC- $\gamma$  (UBI) have also been observed.

The observed changes in protein expression in the immunosuppressed T cells include the complete loss, or

marked decrease, in the expression of the TCR subunit proteins CD3 $\zeta$  and CD3  $\gamma$ ; the appearance of Fc $\epsilon$  $\gamma$ ; and the decreased expression in the signal transduction pathway proteins of these notably Lck, Fyn, PLC- $\gamma$  and GAP.

5 Functional correlates of these include loss in the ability of cells to mobilize Ca<sup>2+</sup> and an altered pattern of tyrosine phosphorylation.

Complete or marked decrease in the expression of CD3 $\zeta$  protein was observed in three human cancer patients

10 exhibiting presence of a tumor for >30 days. Decreased expression of TCR subunit proteins such as CD3 $\zeta$  and CD3  $\gamma$ ; expression of Fc $\epsilon$  $\gamma$  in the T lymphocytes; and decreased expression in signal transduction pathway proteins such as Lck and Fyn correlated with similar changes in T cell

15 function including loss of cytotoxicity and loss in the ability to be stimulated. It is likely that NK cells, which also normally express CD3 $\zeta$  protein, will exhibit decreased immune responsiveness with loss in CD3 $\zeta$  expression.

20 The pattern of NF- $\kappa$ B/rel proteins in melanoma patients revealed alterations from the non-cancerous state. c-rel and p65 were absent in nuclear preparations. These results support use of the NF- $\kappa$ B/rel pattern analysis to detect cancer. Because in animal models,

25 changes in these patterns are detected earlier than changes in the CD3 zeta level of expression, analysis of these patterns may provide earlier detection of cancer in patients than the other assays of the present invention.

Detection prior to clinical signs, that is as a screening assay, is contemplated.

### **Assays for Immunosuppression**

An aspect of the present invention is to provide  
5 assays designed to determine the level of  
immunosuppression. These assays are useful, for example,  
in a patient being evaluated for adoptive immunotherapy,  
or organ transplantation. The assays are performed by  
determining changes in the expression of selected  
10 proteins known to be predictive of the level of  
immunosuppression of T lymphocytes. A selected protein  
to examine in an assay includes any one protein of the  
TCR subunits or the signal transduction pathway, or a  
combination of said proteins. Decreased expression of  
15 selected TCR subunit proteins such as CD3 $\zeta$  and CD3 $\gamma$ ; or  
decreased expression of selected T cell signal  
transduction pathway proteins such as Lck, Fyn, PLC- $\gamma$  or  
GAP; or the increased expression of Fc $\epsilon$  $\gamma$  in T cells or T  
cell subsets, are diagnostic of an immunosuppressed  
20 state. These changes in protein expression in T  
lymphocytes or T cell subsets are associated with loss in  
the ability to stimulate T cells that are needed for  
effective adoptive immunotherapy.

Generally, the association between TCR protein  
25 expression and immunosuppression is positive, i.e., as  
protein expression decreases, so does the response of  
cells to immunotherapy. The response in humans and other  
animals to malignant progression is in the same direction  
as that observed in the murine system.



Analysis of the pattern of TCR subunit proteins, signal transduction pathway proteins, or transcription factors of the NF- $\kappa$ B/rel family of proteins provides an assay for immunosuppression. The pattern includes whether at least one protein is present or absent. The pattern is a vector of 0 or 1, for presence or absence respectively, as determined by Western blots, or similar methods. Antibodies directed to the components of the system are useful to determine if the proteins are present. In some abnormal states, a protein present in the normal state has been replaced by one or more proteins of different molecular weights. In these situations, an antibody directed to the part of the protein that is not present in the replacement proteins, may be used to ascertain whether the substitution has occurred, in which case a complex will not form.

#### Methods for Determining Protein Expression Levels

The expression levels of TCR subunit proteins, of Fc $\epsilon$  $\gamma$ , or of selected proteins in the T cell signal transduction pathway, are suitable for use in an immunosuppression assay. One or a combination of proteins, is used. Many different conventional and well known assay methods are suitable to evaluate the level of expression of selected proteins in T lymphocytes. Samples of tissue or fluid such as blood are isolated from the patient and the level of expression of the selected TCR subunit protein, Fc $\epsilon$  $\gamma$ , or selected protein in the T lymphocyte signal transduction pathway is determined. These samples are taken from various tissues

including tumor tissue, splenic or lymphatic tissue, peripheral blood cells, cerebrospinal fluid, pleural effusions, and ascites.

A protein extract of the tissue or cell sample is  
5 analyzed directly to determine the level of expression of protein. Alternatively, T cells, or T cell subsets, are purified before determining the level of expression of the selected protein. T cells and T cell subsets are purified by any of a variety of conventional techniques  
10 such as rosetting followed by Ficoll-Hypaque gradient centrifugation, indirect panning, antibody/complement-mediated cytotoxicity, immunomagnetic purification, flow cytometry, and similar techniques. Additionally, the TCR are immunoprecipitated using an antibody such as anti-  
15 CD3 $\epsilon$ . The subunit proteins comprising the TCR are analyzed by Western blot by methods known to those of skill in the art.

The level of expression of a protein is determined using well known techniques such as immunofluorescence,  
20 ELISA, Western blot analysis, and similar techniques. An extract for analysis of protein by any of these well known techniques is made by conventional methods from the tissue or fluid sample, or T cells or T cell subsets prepared from these samples. An antibody which  
25 specifically detects the selected protein, and which is conjugated to a known label, is prepared by methods known to those of skill in the art.

**Clinical Evaluation for Organ Transplantation  
Using Protein Expression Assays**

It is contemplated that the methods of the present invention are useful in monitoring and facilitating  
5 transplantation of organs and tissues. A patient is currently prepared for a transplant by means of various treatments designed to increase the level of tolerance. These treatments include repeated transfusions with white blood cells or total blood.

10       Immunosuppression is induced by administering to a patient, the soluble immunosuppressive factor of the present invention in a pharmaceutically acceptable carrier. Effective amounts are determined empirically.

It is possible to monitor the level of expression of  
15 selected TCR subunit proteins, Fc $\epsilon$  $\gamma$ , and proteins in the T lymphocyte signal transduction pathway during preparation of the patient in order to determine the level of immunosuppression in the patient and thereby ascertain when patients are sufficiently immunosuppressed  
20 to receive the transplant.

The methods of the present invention are used to determine the level of immunosuppression in the patient and thereby provide information needed to properly time treatment to maintain tolerance. Agents isolated using  
25 the screening methods of the present invention, capable of increasing immunosuppression in the patient, are expected to have utility for the successful preparation and maintenance of the transplant patient.

### Selection of Patients for Immunotherapy

In determining a therapeutic strategy, a physician assays the expression of TCR-related proteins of a patient's own T lymphocytes in order to evaluate the patient's level of immunosuppression, thereby predicting the likelihood of success that these cells can be stimulated for effective immunotherapy. This is useful for any therapy employing the patient's own cells, e.g. cytokine therapy or autologous adoptive therapy. It is further contemplated that T cells evaluated according to the present invention are selected for allogeneic or syngeneic treatment protocols in cases where a patient's own T cells are immunosuppressed. Even in instances in which adoptive immunotherapy is not contemplated, it is expected that evaluation of the level of immunosuppression will aid the physician in determining when to treat with antibacterial agents, immunostimulating drugs, and the like. Another use is to monitor immunosuppression in autoimmunity or before transplantation to determine the optimal level of suppressive drug being administered as well as the timing of the transplant.

Patients are selected for immunotherapy, for example, for autologous adoptive immunotherapy based on level of expression, or the pattern, of a selected protein or proteins. Selection criteria are that expression levels and/or patterns are not below the threshold for response to lymphocyte stimulation. The threshold level for

response to lymphocyte stimulation is empirically derived for each combination of disease and selected protein and is relative to individuals believed to have normal immunological responses. For example, with one  
5 combination of a selected protein and a particular disease, it may be found that the selected protein must be produced at levels substantially equivalent to that found in healthy individuals in order for autologous adoptive immunotherapy to be effective. With yet another  
10 combination of a selected protein and a disease, autologous adoptive immunotherapy may still be effective with only a relatively low level of expression of the selected protein.

Alternatively, the expression of the gene encoding  
15 the selected protein in T cells or T cell subsets is ascertained by any of a variety of methods including Northern hybridization or *in situ* hybridization. If the gene is known to only be expressed in the T lymphocytes, RNA is isolated from the tissue or cell samples.  
20 Alternatively, RNA may be obtained from purified T cells or T cell subsets prepared from these samples, using conventional methods. The RNA is hybridized with labeled DNA or a hybridization probe which specifically detects the mRNA encoding the selected protein.

25 Alternatively, patients are selected for adoptive immunotherapy on the basis of their protein expression ratio. The expression ratio (E.R.) is the number of T cells which express a selected TCR subunit protein, or protein in the T lymphocyte signal transduction pathway,

divided by the total number of T cells counted. For example, the expression ratio can be determined by means of two-color or three-color flow cytometry according to methods such as those described in *Current Protocols in Immunology*, Vol. I, J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach and W. Strober (eds.), Green Publishing Associates and Wiley-Interscience, 5.1.1-5.4.15 (1991), incorporated herein by reference.

For components of the TCR that are on the interior of the membrane or components of the signal transduction pathway, the cell is made permeable to the label. For example, lymphocytes isolated from the patient are exposed to two different antibodies each of which is conjugated to a different dye. One antibody is used to detect cells expressing the selected TCR subunit protein, or protein in the T lymphocyte signal transduction pathway, and this antibody is conjugated to a dye such as fluorescein isothiocyanate (FITC). A second antibody binds to a protein found in all T cells, such as CD3, and this antibody is conjugated to a second dye such as phycoerythrin. The fraction of T cells expressing the selected TCR subunit protein or T lymphocyte signal transduction pathway protein is determined by analysis of the samples using flow cytometry.

As described in preceding sections, patients are selected for autologous adoptive immunotherapy based on level and/or pattern of protein expression. Selection criteria are that expression is not below the threshold level for response to lymphocyte stimulation, wherein the

threshold level for response to lymphocyte stimulation is empirically derived for each combination of disease and selected protein.

For example, with one combination of selected protein and disease, it may be found that at least 50% of the T cells must express the selected protein (E.R. = 0.5) if autologous adoptive immunotherapy is to be effective. With yet another combination of selected protein and disease, expression of the protein in at least 70% of the T cells (E.R. = 0.7) may be required if autologous adoptive immunotherapy is to be effective. In another combination of selected protein and disease, presence of p65 may be required.

#### **Monitoring Efficacy of Chemotherapy, Radiotherapy and Surgery for Cancer**

If chemotherapy, radiotherapy or surgery is effective in eliminating the majority of a tumor, then the immunosuppressed proteins should return to normal levels and patterns. These improvements are monitored by the methods of the present invention.

It is contemplated that conventional treatments and protocols are used to complement and supplement the methods of the present invention. As the tumor size or load of the patient is decreased using non-biological treatments, e.g. chemotherapy, the level of immunosuppression will also abate. Additionally, agents which reverse immunosuppression are identified by the methods of the present invention. These treatments or agents can be followed or supplemented with autologous adoptive immunotherapy. Effective timing of autologous

adoptive immunotherapy is predicted by measuring the level of immunosuppression in the patient by methods of the present invention, for example, by determining the level of expression of selected TCR subunit proteins; Fc $\epsilon$  $\gamma$  in T lymphocytes; proteins in the T lymphocyte signal transduction pathway; and proteins in the NF- $\kappa$ B/rel family.

The methods that are suitable to supplement or complement autologous adoptive immunotherapy include surgery; radiation or treatment with chemotherapeutic or pharmacological agents. The chemotherapeutic or pharmacological agents include all cytokines; agents which reduce tumor size or load including cyclophosphamide, adriamycin, steroids, flavonoids and IL-2; growth hormones; cimetidine; chloroquine; non-steroidal anti-inflammatories such as aspirin, ibuprofen, indomethacin, and levamisole.

Several different strategies are available to circumvent immunosuppression of T lymphocytes. Immunotherapeutic activity of T lymphocytes are restored by recombinant methods. The level of expression of selected TCR subunit proteins, T lymphocyte signal transduction pathway proteins, or NF- $\kappa$ B/rel are restored in immunosuppressed cells by introducing into said cells an expression vector comprising the gene encoding a selected protein. The expression of a gene in the recombinantly engineered cells restores normal levels of the protein to the lymphocytes. These recombinantly engineered lymphocytes are stimulated for adoptive



immunotherapy using any of the alternative methods herein described.

### **Liposome Delivery System**

Although free cytokines such as IL-2 are suitable for the method of the present invention, a cytokine is preferably incorporated into liposomes as a delivery system. Liposomes are phospholipid vesicles which are capable of containing a designated amount of a cytokine or other bioactive compounds, depending on the type of interaction between a solute and a phospholipid used to prepare a liposome. Methods for the preparation of liposome-encapsulated cytokines are disclosed in co-pending application Serial No. 07/382,778, the disclosure of which is incorporated in its entirety herein by reference.

Several routes of administration are suitable for the administration of liposomes, for example, intravenous, subcutaneous, intraperitoneal, and oral delivery. Important advantages of liposomal delivery include the tissue distribution and binding properties as compared to the free forms of the bioactive ingredient, resulting in enhanced therapeutic index and decreased toxicity.

### **Treatment of Mice with IL-2 Liposomes**

Two experiments have been done treating mice (bearing tumor for 14 days) with intraperitoneal IL2-liposomes (50,000 U/mouse/day x 5 days). The mice were then sacrificed on day 32 after tumor injection, and the splenic lymphocytes were assayed for the expression of  $\zeta$ . Mice receiving IL2-liposomes demonstrated normal levels

of the  $\gamma$  chain whereas non-treated animals had completely lost the expression of this chain. It is possible therefore that IL2-liposomes protect from the loss of  $\gamma$  induced by tumor. However, an alternative possibility is  
5 that the liposomes non-specifically expand T cells such that the loss of  $\gamma$  could be masked by the expanded populations.

### Clinical Use of Stimulated T Cells

In an illustrative embodiment, stimulated T cells are  
10 collected and placed in the body of an organism, preferably a mammal, such as a mouse or a human, where they facilitate immunotherapeutic activity, e.g. cytotoxic activity, or lymphokine production, upon administration of IL-2. More preferably the cells are  
15 placed in the body of a human for immunotherapeutic treatment. The cells are administered to a patient using any of the conventional and well known methods and routes, e.g. those described in S.A. Rosenberg, U.S. Patent No. 4,690,915, incorporated herein by reference.  
20 These routes include intravenous, intraarterial or intracavitary administration, encompassing intrapleural, intraperitoneal, intrathecal, intravesical, and the like.

Generally, after the administration of an effective amount of IL-2 *in vivo*, the cells display an enhanced  
25 proliferation and antitumor activity. The administration of IL-2 preferably occurs over a period of about 7 days. The amount of IL-2 effective for enhancing cell proliferation and immunotherapeutic activity *in vivo* depends on the mammal being treated. For example, about

10,000-70,000 units/day of IL-2, preferably about 50,000 units/day of IL-2, are administered to mice, and about  $1 \times 10^6$  to  $6 \times 10^6$  International Units/m<sup>2</sup>/day are administered to humans.

5       As mentioned in the previous section, it is preferred that the T cells are initially stimulated for less than 24 hours with anti-CD3 MAb, with or without any IL-2 present. It is within the scope of the invention to include IL-2 with the anti-CD3 MAb in the initial  
10 culture, if desired. Although this is suitable and produces similar results, it is not necessarily preferred, at least because of the undesirable expense of IL-2. Rather, it is preferable to stimulate cells with anti-CD3 Mab alone, collect the stimulated cells, infuse  
15 the stimulated cells into an immunosuppressed mammal, and then administer IL-2 to the mammal.

Interleukin-2 is a commercially available T cell growth factor. Both naturally occurring IL-2, such as might be derived from cultured rat splenocytes or from  
20 the Jurkat cell line, or recombinant IL-2 (rIL-2) are suitable. It is believed that other cytokines can also be used in the present invention to produce the cytokine-activated cells. A naturally occurring cytokine, or recombinantly produced cytokine is used. These include  
25 IL-1, IL-4, IL-6, IL-12, TNF, GM-CSF, interferon, and the like. It is envisioned a cytokine may be used alone or in combination with other cytokines, including IL-2, either added to the culturing medium or administered to a patient. Combinations of rIL-2, flavonoids and

chemotherapeutic agents are also effective in reducing tumors, at least in animal models (Wiltrout et al., 1991). T Cells are essential for this anti-tumor response. Commercial sources of recombinant human and murine cytokines are available. *Current Protocols in Immunology*, Vol. I, J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach and W. Strober (eds.), Green Publishing Associates and Wiley-Interscience, 2.4.1-2.10.3 (1991).

10

#### Use of Immunorestorative Agents

It is contemplated that the immunorestorative agents identified using the methods of the claimed invention will have utility in the treatment of diseases characterized by progressive immunosuppression by reversing immunosuppression. These agents are identified by providing a mammalian T lymphocyte preparation wherein the level of expression of at least one selected TCR subunit protein or protein in the signal transduction pathway, or pattern of the NF- $\kappa$ B/rel proteins, is subnormal compared to healthy, non-immunosuppressed individuals of the same mammalian species; the lymphocyte preparation is cultured in the presence of an agent to be tested, generally an agent suspected of reversing immunosuppression; and the level of expression and/or pattern of the selected protein is determined. Alternatively, the agent is administered to a subject with subnormal expression of a TCR subunit protein or protein in the T lymphocyte signal transduction pathway

and the level of expression of said protein is determined in a sample obtained from the patient after treatment.

Agents capable of significantly increasing the level of expression of selected TCR subunit proteins or proteins in the T lymphocyte signal transduction pathway, and/or of restoring the presence of proteins of the NF- $\kappa$ B/rel system, present a method of reversing immunosuppression in a diseased animal or human. The agent is administered to the subject, optionally with or without T cell surface receptor antibodies and/or cytokines for the stimulation of lymphocytes, in order to reverse immunosuppression in the diseased subject. Alternatively, lymphocytes isolated from the subject are treated *in vitro* with the agent and administered to the patient for adoptive immunotherapy. For example, the lymphocytes could be cultured in the presence of flavonoids. These lymphocytes are optionally stimulated *in vitro* or *in vivo*, with or without T cell surface receptor antibodies and/or cytokines.

Subgroups of patients may be identified and evaluated which may not show a response to one combination of agents, but may to others. Non-responders to anti-CD3, for example, may respond if flavonoids and IL-2 are added. The additional agents may "rescue" patients previously intractable to therapy.

#### **Restoration of Immunological Function Using Recombinant Techniques**

Methods known to those of skill in the art are used for the construction of an expression vector carrying the selected gene of interest as well as for the introduction

of said vector into immunosuppressed T cells. To restore immunological function, a gene encoding an immunorestorative agent is included in the vector. This gene could be an antisense gene to the immunosuppressive factor of the present invention. The gene is operably linked to a promoter, which is generally a regulatable promoter. The vector is introduced into T lymphocytes using well known transfection protocols such as calcium phosphate transfection or transfection by electroporation. The selected gene is introduced and expressed in T cells using well known vectors, e.g. retroviral vectors. *Current Protocols in Molecular Biology*, F.M. Ausubel et al. (eds.), Greene Publishing Associates and Wiley-Interscience, 9.0.1-9.14.3 (1989).

#### Reexpression of the CD3 $\zeta$ Chain

Culturing of lymphocytes from tumor-bearing mice for 48 hours in tissue culture media (RPMI 1640 + additives, but no fetal bovine serum) containing any of the following combinations induces a re-expression of the CD3 $\zeta$  chain:

- A. Ionomycin (1  $\mu$ g/ml) (Calbiochem, La Jolla, CA)
- B. Ionomycin + Phorbol Miristic Acetate (10 ng/ml) (Chemsyn Science Labs., Lenexa, Kansas).
- C. Ionomycin + IL2 (300 U/ml).
- D. Ionomycin + PMA + IL2
- E. Ionomycin + anti-CD3 + IL2
- F. Anti-CD3 monoclonal antibody (10 ng/ml)
- G. Flavonoids + IL-2
- H. Anti-CD3 + flavonoids

### Use of Immunosuppressive Agents

Immunosuppressive agents identified using the methods of the claimed invention are likely to have utility in the treatment of autoimmune diseases. Of particular interest in this regard are soluble factors produced by a tumor which cause T cell immunosuppression. These agents are identified by providing a mammalian T lymphocyte preparation wherein the level of expression of at least one selected TCR subunit protein, or protein in the signal transduction pathway is normal compared to healthy individuals of the same mammalian species. Another assay is whether alterations are present in the pattern of NF- $\kappa$ B/rel proteins. The lymphocyte preparation is cultured in the presence of an agent suspected of causing immunosuppression, and the level of expression and/or pattern of said protein is determined. Alternatively, the agent is administered to a healthy subject and the level of expression of at least one selected TCR subunit protein or protein in the lymphocyte signal transduction pathway is determined. The agents are isolated and further purified by fractionating the immunosuppressive supernatant to locate the active fraction, and applying methods of qualitative analysis to identify the nature of the factor.

Agents capable of decreasing the level of expression of selected TCR subunit proteins or proteins in the T lymphocyte signal transduction pathway, and/or the pattern of NF- $\kappa$ B/rel proteins, present a method of inducing immunosuppression in an animal or human. The

agents or the soluble immunosuppressive factor of the present invention are administered to the subject. Alternatively, a nucleotide sequence encoding at least the immunosuppressive sites of the soluble factor, is  
5 transfected into cells, generally cells of the recipient, and administered to the mammal.

The following examples are set forth as representative of specific and preferred embodiments of the present invention. These examples are not to be  
10 construed as limiting the scope of the invention in any manner. It should be understood that many variations and modifications can be made while remaining within the spirit and scope of the invention.

#### Example 1

##### 15      **Loss of Antitumor Effects of T Cells Isolated From Long-Term Tumor-Bearing Mice**

T cells isolated from long-term TBM have no detectable antitumor effects when used in adoptive immunotherapy ("Long-term" is used interchangeable with  
20 "late" herein). The generation of T-activated killer (T-AK) cells was accomplished as described in C.M. Loeffler et al., *Cancer Res.*, 51: 2127 (1991), which is incorporated herein by reference. C57BL/6 murine splenocytes were placed on a Ficoll-Paque gradient  
25 (Pharmacia) for isolation of lymphocytes. After washing with HBSS (GIBCO, Grand Island, NY) two times, red blood cells (RBC) were lysed with distilled water and the remaining mononuclear cells counted. The cells were then placed over a mouse T cell rapid affinity chromatography  
30 column (Biotex Laboratories Inc., Edmonton Canada) for T



cell enrichment. Cells were washed with HBSS two times, activated with anti-CD3 MAb (145-2C11) and IL-2 (specific activity,  $1.5 \times 10^7$  U/mg; Hoffmann-LaRoche Inc., Nutley, NJ). T-enriched cells were incubated in culture flasks at a concentration of  $1.5 \times 10^6$  cells/ml of TCM consisting of Rosewell Park Memorial Institute (RPMI) 1640 (available from GIBCO, Grand Island, NY) supplemented with 25 mM HEPES [N-2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)], 2 mM L-glutamine, 5% fetal calf serum, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, 10 mM non-essential amino acids, 100 mM sodium pyruvate, and 25  $\mu$ M 2-mercaptoethanol. To generate T-AK cells, 2  $\mu$ g of 145-2C11 MAb was added per ml of TCM. Cells were incubated overnight at 37°C in 5% CO<sub>2</sub> after which they were harvested, washed twice in HBSS, resuspended in HBSS containing 30 U/ml of IL-2, counted and injected into mice.

Methods for demonstrating the therapeutic efficacy of T-AK cells used in conjunction with liposome-encapsulated IL-2 (IL-2 liposomes), were done as described in C.M. Loeffler et al., *Cancer Res.*, 51: 2127 (1991), which is incorporated herein by reference. Approximately  $3.0 \times 10^5$  MCA-38 cells in 0.5 ml of HBSS were injected intrasplenically in 6- to 8-week old C57BL/6 mice using a 30-gauge needle. Each experimental group consisted of at least 10 C57BL/6 mice. After three days, mice received a single intravenous injection of  $4.0 \times 10^7$  T-AK cells from either normal mice, early TBM (subcutaneous tumor present for 14-21 days) or late TBM

(subcutaneous tumor present for greater than 30 days). In addition, mice received once-daily intraperitoneal injections of IL-2 liposomes (50,00 U per day) on days 3-7 following tumor inoculation. The number of hepatic metastases was evaluated in each therapeutic group on day 12 after tumor inoculation. One to 2 ml of a 15% India ink solution was injected into the superior mesenteric vein of anesthetized mice. The liver was removed and placed in Fekete's solution (30 ml formalin and 15 ml glacial acetic acid in 300 ml of 70% ethanol). Hepatic metastases were counted and a Student's unpaired T-test was used to evaluate the significance of differences between treatment groups.

The data presented in FIG. 1 illustrates representative results obtained in three separate experiments. Untreated mice had  $236 \pm 30$  liver metastases by day 11. Mice treated with T-AK cells from a non-tumor-bearing mouse (normal) had  $99 \pm 23$  metastases while T-AK cells from early TBM produced an even greater reduction in the number of metastases to  $48 \pm 16$ . T-AK cells obtained from late TBM failed to produce any therapeutic effect because hepatic metastases numbered  $229 \pm 41$ . The therapeutic efficacy of T-AK cells is therefore dramatically reduced when these cells are obtained from late TBM.

Example 2**Significant Decrease in In Vitro Cytotoxicity in  
T Lymphocytes from Long-Term TBM**

The *in vitro* cytotoxicity of lymphocytes from long-term TBM is significantly decreased from the non-malignant state. Standard chromium release assays were performed using as effectors, T-AK cells which were maintained in culture with 100 U of rIL-2 after the initial stimulation with anti-CD3. Assays were performed on days 2, 4, and 7 of culture. Tumor targets ( $4 \times 10^6$ /ml) were incubated with 150  $\mu$ Ci  $\text{Na}_2^{51}\text{CrO}_4$  (1000  $\mu$ Ci/ml; New England Nuclear Products, Boston, MA) at 37° C for 60 min. The targets were washed twice with TCM, resuspended in media, and counted. T-AK effector cells were washed twice and then aliquoted in triplicate in U-bottom microtiter plates (Costar) and serially diluted 2-fold to yield effector:target cell ratios ranging from 24:1 to 3:1. Five thousand targets were added per well. Spontaneous release wells contained target cells in culture media only. The maximum release well contained target cells in detergent. Plates were incubated for 4 h at 37° C in 5%  $\text{CO}_2$ . The supernatant was harvested and radioactivity was counted in a gamma counter (LKB 1272). The percentage of specific cytotoxicity was determined by the formula:

$$\frac{\text{Experimental mean cpm} - \text{spontaneous mean cpm}}{\text{Maximal mean cpm} - \text{spontaneous mean cpm}} \times 100 = \% \text{ of cytotoxicity}$$

At day 2 of culture, cytolytic activity was consistently highest in the early TBM cells (FIG. 2) while that of both non-tumor-bearing (normal) or late TBM

cells was lower. Lytic function of cells from normal mice on day four of culture had increased significantly, but it was still highest in early TBM (FIG. 3). Late TBM lymphocytes had the lowest lytic function.

5           Only after 7 days in culture did lymphocytes from late TBM show any significant increase in lytic function (FIG. 3). Lytic activity was also observed against the syngeneic target MBL2 (lymphoma) and an allogeneic target, RENCA (renal cell carcinoma). The absolute  
10       levels of cytotoxicity varied with the targets, but early TBM cells were consistently the most lytic, and the late TBM cells always had the lowest activity.

          Cytotoxicity assays were performed using CD8<sup>+</sup>-enriched preparations from early and late TBM. Enriched  
15       T cell preparations were made by passing a single cell splenocyte suspension through a T cell column (Biotex Laboratory Inc., Edmonton, Canada) following the kit instructions. To enrich for CD8<sup>+</sup> cells, T-enriched cells were incubated with 1 µg/1.0 x 10<sup>6</sup> cells of anti-L3T4  
20       (500 µg/ml; Becton Dickinson, Mountain View, CA) for 30 min at 4° C. The cells were washed twice in HBSS. Goat anti-mouse IgG Fc-specific coated magnetic beads (Advanced Magnetix Inc., Cambridge, MA) were washed with PBS twice and incubated with PBS and mixed with the T-  
25       enriched cells at a bead:cell ratio of 25:1 at 4° C for 30 min and then separated on a magnetic separator (Advanced Magnetix). The last step was repeated twice. Unbound cells were removed and washed twice with HBSS. CD8<sup>+</sup>-enriched cells had less than 2% CD4<sup>+</sup> contaminating

cells. Phenotypic analysis of the enriched cell preparations showed greater than 95% CD8<sup>+</sup>.

CD8<sup>+</sup>-enriched cells showed lytic activity similar to that of unseparated lymphocytes (Table 1). To eliminate the potential confounding effects of even small numbers of contaminating cells, CD8<sup>+</sup> cells were also positively sorted by FACS, cultured with anti-CD3 + IL-2 and tested for lytic function. Positive cell selection by FACS was performed with T-enriched cells from fresh splenocyte preparations (greater than 95% Thy 1.2<sup>+</sup> cells). These cells were incubated with 1  $\mu$ g/1.0 x 10<sup>6</sup> cells of anti-Lyt.2 FITC and anti-L3T4 (500  $\mu$ g/ml; Becton Dickinson) for 30 min at 4° C. The cells were then sorted into FITC<sup>+</sup> (CD8<sup>+</sup> cells) and PE<sup>+</sup> (CD4<sup>+</sup> cells) on a FACStar Plus flow cytometer (Becton Dickinson).

The lytic activity of the early TBM CD8<sup>+</sup> lymphocytes was again the highest while that of late TBM cells was the lowest (Table I). In all experiments, the results remained similar regardless of whether the effector cells were enriched T cells, enriched CD8<sup>+</sup> or pure CD8<sup>+</sup> cells. The increase in cytotoxicity seen in late TBM CD8<sup>+</sup> cells after seven days in culture may be due to an increase in the lytic function of the originally suppressed CD8<sup>+</sup> cells or due to the expansion of a small subset of CD8<sup>+</sup> cells which were never suppressed.

TABLE I

Cytotoxic activity of T cells from  
normal mice, early TBM, and late TBM<sup>a</sup>

|    |                                                    | <u>Lytic U/10<sup>7</sup> cells</u> |
|----|----------------------------------------------------|-------------------------------------|
|    | T enriched cells                                   |                                     |
| 5  | Normals                                            | 259                                 |
|    | Early TBM                                          | 319                                 |
|    | Late TBM                                           | 189                                 |
|    | CD8 <sup>+</sup> cells (CD4 <sup>+</sup> depleted) |                                     |
|    | Normals                                            | 254                                 |
| 10 | Early TBM                                          | 469                                 |
|    | Late TBM                                           | 162                                 |
|    | CD8 <sup>+</sup> cells (positive sort)             |                                     |
|    | Normals                                            | 278                                 |
|    | Early TBM                                          | 1161                                |
| 15 | Late TBM                                           | 125                                 |

<sup>a</sup> Cytolytic activity of T-enriched, CD8<sup>+</sup> cells obtained by CD4<sup>+</sup> depletion or cell storing. Cells were activated with anti-CD3 and cultured in TCM with 100 U IL-2/ml for 3 days.

Example 3

**Phenotypic Analysis of T-Enriched Cell Preparations  
from Fresh Splenocytes of Normal Mice, Early TBM and Late  
TBM**

5           The abnormal activity of late TBM cells is not  
related to large alterations in T cell subsets or  
distributions. To determine if a difference in the  
percentage of T-lymphocyte subsets could explain the  
difference in lytic function, phenotyping was done in the  
10       following manner. Fresh splenocytes from the various  
groups of mice were enriched for T cells and purified to  
remove contaminating tumor cells. The data was obtained  
from cell preparations that were greater than or equal to  
95% Thy 1.2<sup>+</sup>.

15           There was a consistent, but not significant decrease  
in the L3T4<sup>+</sup> populations from late TBM (Table II). The  
CD4/CD8 ratios in these mice, however, remained within  
normal limits. The phenotypes of fresh splenocytes not  
enriched for T cells, obtained from the same groups of  
20       mice, did not show any significant change in the cell  
subsets. Large alterations in T cell subsets or  
distribution, therefore, is not related to the abnormal  
activity of late TBM.

TABLE II

Phenotypic analysis of T-enriched cells from  
normal mice, early TBM, and late TBM<sup>a</sup>

|           | <u>Thy 1.2</u> | <u>CD 3</u> | <u>Lyt.2</u> | <u>L3T4</u> | <u>Mac 1</u> |
|-----------|----------------|-------------|--------------|-------------|--------------|
| Normals   | 98%            | 86%         | 37%          | 54%         | 2%           |
| Early TBM | 97%            | 89%         | 30%          | 58%         | 3%           |
| Late TBM  | 95%            | 86%         | 34%          | 48%         | 3%           |

<sup>a</sup> Phenotypic analysis of T-enriched cells from normal and tumor-bearing mice (TBM). Flow cytometry was performed on T lymphocytes isolated from spleens of mice bearing tumor for different lengths of time. T lymphocytes were enriched on a T cell column (Collect, Biotex) immediately after isolation.

#### Example 4

No Major Differences Were Observed in the Levels of Lymphokines in Supernatants of Activated T-Enriched Cells from Normal Mice, Early TBM and Late TBM

In order to determine if inadequate function of the CD4<sup>+</sup> helper cell subset was the principal cause of the decreased immunological responsiveness in late TBM, lymphokine levels in the supernatants of activated T-enriched cells from normal mice, early TBM and late TBM were compared. Samples of supernatants were collected at 24, 48 and 72 h. IL-1 $\alpha$  was measured using mouse Interest



I- $\alpha$  Elisa (Genzyme, Cambridge, MA). Biologically active protein was confirmed using the IL-1 mouse thymocyte bioassay. IL-2 levels were tested with the IL-2 Elisa Kit (Collaborative Research, Inc., Bedford, MA) and confirmed with the IL-2 bioassay using the IL-2-dependent cell line, CTLL-2 (ATCC). IL-6 levels were measured with the murine IL-6 Elisa Kit (Endogen Inc., Boston, MA) and confirmed with the murine bioassay utilizing the plasmacytoma cell line T1165 (Genetics Institute). Total murine interferons were measured with the L929 (ATCC) virus bioassay. TNF- $\alpha$  levels were measured with the 1929 mouse fibroblast cell line (ATCC).

There were no major differences in the levels of lymphokines measured in the early and late TBM T-AK cultures in three different experiments. The data after 48 h in culture, from two of these experiments, is shown in Table III. Significant differences in lytic function were observed in these same experiments. Lymphokine production was therefore quantitatively and qualitatively similar in the supernatants of activated T-enriched cells from normal mice, early and late TBM.

TABLE III

Lymphokine levels in supernatants of activated T-enriched cells from normal mice, early TBM and late TBM<sup>a</sup>

|                      | IL-1 <sup>b</sup> | IL-2 <sup>c</sup> | IL-6 <sup>b</sup> | IFN <sup>c</sup> |
|----------------------|-------------------|-------------------|-------------------|------------------|
| <u>Experiment #1</u> |                   |                   |                   |                  |
| 5 Normal             | 24                | 3.0               | 850               | 20               |
| Early TBM            | 48                | 6.5               | 1000              | 60               |
| Late TBM             | 40                | 6.0               | 1250              | 40               |
| <u>Experiment #2</u> |                   |                   |                   |                  |
| Normal               | 0                 | 4.5               | 1200              | 16               |
| 10 Early TBM         | 90                | 7.5               | 1250              | 130              |
| Late TBM             | 75                | 9.0               | 1250              | 180              |

<sup>a</sup> Lymphokine levels in supernatants of T-enriched cells from normal and TBM activated with anti-CD3. Samples were obtained at 24, 48, and 72 h. Data presented are from 48 h.

<sup>b</sup> pg/ml

<sup>c</sup> I.U./ml

#### Example 5

**CD4<sup>+</sup> Cells from Late TBM Have Adequate Helper Function.**

20 CD4<sup>+</sup> lymphocytes in late TBM are more active as helper cells than CD4<sup>+</sup> cells from normal animals. Mixing experiments were done to test whether CD4<sup>+</sup> cells from

late TBM would enhance or suppress the development of lytic function in normal CD8<sup>+</sup> cells. Purified CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes were cocultured in 24 mm wells separated by a membrane with 4  $\mu$ m size pores. This pore size  
5 allows for free exchange of soluble components. Cytotoxicity assays were performed on day 2 of culture.

CD8<sup>+</sup> cells from normal mice showed an increased lytic activity (655 L.U.) when cocultured with CD4<sup>+</sup> cells from late TBM compared to their lytic activity (204 L.U.) in  
10 the presence of normal CD4<sup>+</sup> cells (Table IV). CD4<sup>+</sup> cells from late TBM were able to support the high lytic function of early TBM CD8<sup>+</sup> lymphocytes (1075 L.U.) even better than normal CD4<sup>+</sup> cells (482 L.U.). CD4<sup>+</sup> lymphocytes are not responsible for suppressing the  
15 function of CD8<sup>+</sup> cells in late TBM because these cells are more active as helper cells than CD4<sup>+</sup> cells from normal animals.

TABLE IV

CD4<sup>+</sup> cells from late TBM do not suppress lytic function  
in CD8<sup>+</sup> cells<sup>a</sup>

| 5  | <u>Source of Cells</u>             |                                    |                                    | <u>Lytic U/10<sup>7</sup> cells</u> |
|----|------------------------------------|------------------------------------|------------------------------------|-------------------------------------|
|    | <u>Late TBM</u>                    | <u>Early TBM</u>                   | <u>Normal</u>                      |                                     |
|    | CD4 <sup>+</sup> /CD8 <sup>+</sup> | --                                 | --                                 | 139                                 |
|    | --                                 | CD4 <sup>+</sup> /CD8 <sup>+</sup> | --                                 | 1375                                |
|    | --                                 | --                                 | CD4 <sup>+</sup> /CD8 <sup>+</sup> | 204                                 |
|    | --                                 | CD8 <sup>+</sup>                   | CD8 <sup>+</sup>                   | 1058                                |
| 10 | CD8 <sup>+</sup>                   | CD4 <sup>+</sup>                   | --                                 | 354                                 |
|    | CD4 <sup>+</sup>                   | --                                 | CD8 <sup>+</sup>                   | 655                                 |
|    | CD4 <sup>+</sup>                   | CD8 <sup>+</sup>                   | --                                 | 1075                                |
|    | CD8 <sup>+</sup>                   | --                                 | CD4 <sup>+</sup>                   | 104                                 |
|    | --                                 | CD8 <sup>+</sup>                   | CD4 <sup>+</sup>                   | 482                                 |

15   <sup>a</sup> Mixing experiments were performed by combining freshly  
isolated cell subsets in 24mm wells after stimulation  
with anti-CD3 and IL-2. Experiments were also performed  
utilizing Costar "Transwell" plates where the subsets are  
separated by a membrane containing 0.4  $\mu$ m pore size.  
20   Lytic function was tested against MBL2 lymphoma three  
days after starting the culture.

Example 6**CD8<sup>+</sup> Cells from the Late TBM Do Not Suppress Other CD8<sup>+</sup> Cells.**

CD8<sup>+</sup> cells from late TBM are defective. CD8<sup>+</sup> cells from late TBM are poor in lytic activity when cocultured with CD4<sup>+</sup> cells from any source. When cocultured with the most highly active CD4<sup>+</sup> cells from early TBM, CD8<sup>+</sup> cells from late TBM had 1/3 to 1/4 the total lytic activity of CD8<sup>+</sup> cells from normal mice or early TBM. Coculture experiments performed in regular 24 mm wells which permit cell-cell contact between CD4<sup>+</sup> and CD8<sup>+</sup> cells showed very similar results where once again, CD8<sup>+</sup> cells from late TBM had 1/3 to 1/4 the total lytic activity of CD8<sup>+</sup> cells from normal mice or early TBM. Mixing experiments using CD8<sup>+</sup> cells from early and late TBM gave no indication that CD8<sup>+</sup> cytolytic activity is suppressed by other CD8<sup>+</sup> suppressor cells. Even in the presence of adequate helper function CD8<sup>+</sup> cells from late TBM were weakly cytotoxic suggesting that CD8<sup>+</sup> cells are the target of tumor-mediated immune suppression.

Example 7**Inhibition of Cytotoxic Activity of Normal Cells by Supernatants from MCA-38 Cell Cultures**

The absence of suppressor activity within the lymphocyte subsets from late TBM suggested that the inhibiting signal(s) might originate from the tumor itself. Titration experiments were performed using increasing concentrations of supernatants from MCA-38 cell cultures making sure the concentration of IL-2 was kept constant. Lymphocytes were activated with anti-CD3 and cultured with 100 U/ml of IL-2. Cultures were

started at  $1.5 \times 10^6$  cells/ml and cell counts and cytotoxicity assays were performed on day 3 of culture.

The cytolytic activity of lymphocytes cultured in media containing as little as 30% supernatant from MCA-38  
5 cells was decreased by 30-45% (Table V). TGF- $\beta$  is a tumor-associated cytokine that has been implicated in tumor-mediated immune suppression. Antibodies to TGF- $\beta$ , however, did not diminish the inhibitory effects of the tumor supernatant. Two bioassays failed to detect any  
10 TGF- $\beta$  activity in the tumor supernatant.

Similar inhibitory effects were mediated by supernatants of the MBL-2 lymphoma. The inhibitory effects of the tumor is therefore not limited to the MCA-38 model system. These data suggest that a soluble tumor  
15 product(s) inhibits the development of cytotoxic function in CD8<sup>+</sup> cells in late TBM.

TABLE V

Suppression of in vitro cytolytic activity of normal lymphocytes by tumor cell supernatant<sup>a</sup>

|                 | <u>Lytic U/10<sup>7</sup> cells</u> |        |        |
|-----------------|-------------------------------------|--------|--------|
|                 | Exp. 1                              | Exp. 2 | Exp. 3 |
| Normals         | 138                                 | 93     | 118    |
| 10% supernatant | 126                                 | 116    | 126    |
| 30% supernatant | 99                                  | 89     | 66     |
| 50% supernatant | 83                                  | 48     | 21     |

<sup>a</sup> Suppression of cytolytic activity of normal lymphocytes by supernatant of MCA-38 cells in culture. Lymphocytes were activated with anti-CD3 and cultured with 100 U/ml of IL-2. Various concentrations of supernatant from MCA-38 tumor cultures were titrated into the cell cultures. Cultures were started at  $1.5 \times 10^6$  cells/ml and cell counts and cytotoxicity assays were performed on day 3 of culture.

#### Example 8

#### Expression of RNA Encoding for Cytolytic Proteins Granzyme B and TNF- $\alpha$

Whole cellular RNA from enriched T lymphocytes from normal mice, and early and late TBM were analyzed at different time points during culture by Northern hybridization in order to assess whether the decreased lytic function of T-AK from late TBM was related to the production of cytolytic effector molecules.

Additionally, the CD4<sup>+</sup> and CD8<sup>+</sup> subsets obtained by depletion were also analyzed. The expression of RNA encoding TNF- $\alpha$ , granzyme B, IL-2, IL-2R, IFN- $\gamma$  and IL-6 was determined. An 18S RNA was used to determine the relative quantities of RNA loaded onto the gels. To compensate for differences in loading, densitometric ratios between the expression of 18S and granzyme B of TNF- $\alpha$  were done.

The expression levels of IL-2, IL-2R, IFN- $\gamma$  and IL-6 RNA were identical in the early and late TBM lymphocytes. The level of granzyme B mRNA, however, was 10-fold higher in the CD8<sup>+</sup> cells from early TBM at 36 h of culture than in CD8<sup>+</sup> from late TBM. The level of granzyme B mRNA in CD8<sup>+</sup> cells from late TBM was also significantly lower than in normal CD8<sup>+</sup> cells at 36 h as measured by densitometry. The expression of mRNA encoding granzyme B in the CD8<sup>+</sup> cells from late TBM increased to levels comparable to that seen in early TBM at 36 h of culture only by day 8 of culture. It is not known whether the cells expressing granzyme B on day 8 in the late TBM cells were a small subset of cells which proliferated to detectable levels by day 8 or whether time in culture allowed the CD8<sup>+</sup> cells to recover and regain cytolytic function.

The expression of TNF- $\alpha$  mRNA was also highest in the T lymphocytes of early TBM, measured at 36 h of culture, compared to that of normal mice or late TBM. The expression of TNF- $\alpha$  mRNA in T lymphocytes from late TBM



increased to levels comparable to that seen in early TBM at 36 h of culture only by day 8 of culture.

Example 9

5           **Marked Changes in the Expression of CD3 $\delta$  and CD3 $\gamma$  in T Lymphocytes from Late TBM**

Expression of the TCR-CD3 complex was also measured by fluorescence intensity of the T cells after labelling with control fluorescein labeled IgG2A, anti-mouse  $\alpha\beta$  (Pharmingen) or anti-CD3 (145-2C11). Phenotypic analysis  
10 demonstrated that the purified T cells from late TBM were CD3 $^{+}$  (97%), Thy 1.2 $^{+}$  (98%),  $\alpha\beta^{+}$  (98%), NK1.1- (<1%) with a normal CD4 (L3T4 $^{+}$ )/CD8(Lyt2 $^{+}$ ) ratio. A comparison of the TCR-CD3 complex of T cells from normal mice and late TBM revealed no apparent changes in the expression of the  
15 TCR-CD3 complex as suggested by the fluorescent intensity. The antibodies used for phenotyping the TCR, however, only bind to one each of the seven chains in the TCR-CD3 complex.

Further evaluation of the TCR-CD3 complex was done  
20 by surface labeling with  $^{125}$ Iodine, immunoprecipitation with anti-CD3 (145-2C11) and resolution by 2-D non-reducing-reducing SDS-PAGE. Approximately  $5 \times 10^7$  T lymphocytes from normal mice and late TBM were labeled with  $^{125}$ Iodine by the lactoperoxidase-glucose oxidase  
25 method. *Current Protocols in Immunology*, Vol. I, J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach and W. Strober (eds.), Green Publishing Associates and Wiley-Interscience, 8.11.1-8.11.4 (1991). After labeling, the TCR complexes were precipitated with 145-2C11 MAb,  
30 absorbed to protein G-sepharose and resolved by 2D non-

reducing-reducing 14% SDS-PAGE. Major changes in the TCR-CD3 components from T cells from late TBM were apparent. The CD3 $\zeta$  subunit protein was absent and there was a marked decrease in CD3 $\gamma$ . Additionally, a faint  
5 spot below the diagonal corresponding to a small protein was present which suggested that an Fc $\epsilon$  $\gamma$  chain was associated with the TCR-CD3 complex. E. Reinherz, *J. Exp. Med.*, 175: 203 (1992).

Surface expression of the TCR-CD3 complex of T  
10 lymphocytes from normal and late TBM was analyzed. T lymphocytes from normal mice expressed the  $\alpha\beta$  Ti complex; the  $\delta$ ,  $\epsilon$  and  $\gamma$  chains of the CD3; as well and the  $\zeta$  homodimer. T lymphocytes from late TBM, however, do not express the CD3 $\zeta$  or CD3 $\gamma$  chains.

15 Western blots using anti- $\zeta$  or anti-Fc $\epsilon$  $\gamma$  confirmed these observations. Approximately  $2 \times 10^7$  T cells from normal and late TBM were solubilized in lysis buffer (25 mM Tris pH7.4, 150 mM NaCl, 0.5% Triton-X 100, 1 mM sodium orthovanadate, 10 $\mu$ g/ml aproptinin, 10  $\mu$ g/m;  
20 leupeptin and 5 mM EDTA). The lysate was centrifuged and the supernatant was immunoprecipitated with rabbit anti- $\zeta$  antiserum, control normal rabbit serum, anti-CD3 $\epsilon$  (145-2C11 MAb) or control anti-human CD4 (OKT4). Immunoprecipitate was resolved by SDS-PAGE and blotted  
25 with anti- $\zeta$  rabbit serum. T lymphocytes from late TBM lost the expression of the  $\zeta$  chain and expressed the Fc $\epsilon$  $\gamma$  chain normally not seen in T cells. The TCR in T cells from late TBM was therefore  $\alpha\beta$ ,  $\delta\epsilon$ , Fc $\epsilon$  $\gamma_2$  instead of the

$\alpha\beta$ ,  $\gamma\delta\epsilon\zeta_2$  seen in normal T lymphocytes. T lymphocytes from early TBM were not tested for TCR-CD3 structure.

Western blot analysis of T lymphocytes from late TBM revealed that  $\zeta$  protein expression was undetectable in these cells. T lymphocytes from normal mice and early TBM, isolated under the same conditions, expressed normal levels of  $\zeta$  protein. Thus, an important component in the TCR is absent from the TCR of T lymphocytes from late TBM. The loss of  $\zeta$  protein expression in T lymphocytes from late TBM is correlated with the loss of *in vitro* cytotoxic and *in vivo* immunotherapeutic activity.

T lymphocytes from late TBM, however, expressed normal levels of TCR as determined by immunofluorescence with anti  $\alpha\beta$  and anti- $\epsilon$ . Western blotting with anti-Fc $\epsilon\gamma$  revealed the unique expression of this member of the  $\zeta$  family in T lymphocytes from late TBM. The expression of Fc $\epsilon\gamma$  in T lymphocytes from late TBM may explain the presence in these cells of normal levels of TCR in their membrane.

20

#### Example 10

##### **Aberrant Signal Transduction in Lymphocytes from Late TBM.**

T lymphocytes from late TBM exhibit an altered form of signal transduction. This is evident from the fact that T lymphocytes from late TBM exhibit a significant decrease in their ability to mobilize  $\text{Ca}^{2+}$  as compared to T lymphocytes from normal mice or late TBM. Calcium flux was measured in T lymphocytes by calcium sensitive fluorescence and the calcium concentration was estimated according to *Current Protocols in Immunology*, Vol. I,

30

J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach and W. Strober (eds.), Green Publishing Associates and Wiley-Interscience, 5.5.1-5.5.15 (1991), incorporated herein by reference. Approximately  $1 \times 10^7$  T cells were loaded with Indo 1 and stimulated with 10 ng/ml anti-CD3 MAb (145-2C11). Maximal flux was determined after lysis with calcium ionophore. Maximal fluorescence was determined after lysis with Triton-X 100 and minimum fluorescence after calcium chelation with EGTA.

Stimulation of lymphocytes from late TBM with anti-CD3 MAb revealed a significantly decreased ability to mobilize  $\text{Ca}^{2+}$  as compared to those from normal mice or from early TBM. Even prolonged incubation with anti-CD3 (400 seconds) was not enough to achieve the levels of  $\text{Ca}^{2+}$  flux seen in T cells from normal or early TBM. Stimulation of T lymphocytes from late TBM with calcium ionophore, however, resulted in equivalent maximum  $\text{Ca}^{2+}$  flux demonstrating adequate intracellular stores in the cells.

Additionally, the pattern of phosphorylation of tyrosine residues in T lymphocytes from late TBM was markedly different compared to that of cells from normal mice or early TBM. Approximately  $1 \times 10^7$  cells were stimulated in serum free medium with 10 ng/ml of anti-CD3 (145-2C11) for 2 minutes. The reaction was stopped by washing the cells twice in ice-cold phosphate-buffered saline containing 400  $\mu\text{M}$  sodium orthovanadate and 1 mM EDTA. Cells were lysed in 100  $\mu\text{l}$  of lysis buffer (25 mM

Tris pH7.4, 150 mM NaCl, 0.5% Triton-X 100, 1 mM sodium orthovanadate, 10 $\mu$ g/ml aprotinin, 10  $\mu$ g/m; leupeptin and 5 mM EDTA) for 5 min. on ice. Lysate were centrifuged and supernatants were analyzed by 10.5% SDS-PAGE under reduced conditions. Proteins were electrophoretically transferred onto PVDF filter (Imobilon-P), blocked with 5% gelatin in TBST buffer (20 mM Tris pH 7.4, 135 mM NaCl, 0.1% Tween 20) and incubated with anti-phosphotyrosine MAb (40 ng/ml). After washing, the blots were incubated with anti-mouse Ig MAb conjugated with peroxidase, subjected to ECL kit (Amersham) and exposed to an X-ray film.

The basal pattern of phosphorylated tyrosine residues was markedly altered in T lymphocytes from late TBM as compared to the other two groups. Changes in the residues in the 40-52 Mr range were consistently seen in three experiments. Stimulation with anti-CD3, however, induced the phosphorylation of tyrosine residues, demonstrating an effective signal transduction.

No differences were detected between normal purified splenic T cells and those from tumor-bearing mice in fluorescence intensity (an indicator of receptor number) or in percentage of cells expressing the TCR $\alpha$ B heterodimer (FIG. 4A) or the CD3 complex (FIG. 4B). Flow cytometry demonstrated that splenic T cells from tumor-bearing mice express Thy 1.2 (98%) and TCR $\alpha$  $\beta$  (98%); and have a normal CD4/CD8 ratio. They did not express NK cell markers: NK1.1 was <1%. CD16 (Fc receptors) was <1%. No skewing of the T cell receptor repertoire was

detected when  $V_{\beta}$  gene usage was examined in splenic T cells. Binding of ligand to the TCR causes  $Ca^{2+}$  mobilization. Weiss, (1990), *J. Clin. Invest.* 86, 1015. In contrast to T cells from normal mice, those from  
5 tumor-bearing mice had a blunted calcium response when stimulated with monoclonal antibody to CD3 (anti-CD3). The response did not improve with prolonged times of incubation (400 s) (FIG. 4A). However, stimulation with calcium ionophore (Indo-1) resulted in equivalent maximum  
10  $Ca^{2+}$  concentration flux in normal T cells and in those from tumor-bearing mice. Thus, the cells from tumor-bearing mice had adequate intracellular  $Ca^{2+}$  stores and loading of Indo-1. Analysis of purified  $CD4^{+}$  and  $CD8^{+}$  T cell subsets showed quantitatively similar defects in  
15 each subset. These T cells did not optimally release intracellular  $Ca^{2+}$  stores in response to signalling through the TCR even though surface TCR density was normal.

#### Example 11

#### 20 **Expression of Lck and Fyn is Undetectable or Diminished in T Lymphocytes from Late TBM.**

Protein tyrosine phosphorylation is the earliest demonstrable event in TCR-mediated signalling, preceding phosphatidylinositol hydrolysis,  $Ca^{2+}$  mobilization, and  
25 later functional events such as cytokine secretion and cytokine receptor expression (June et al., 1990 *P.N.A.S.* 87:7722, *J. Immunol.* 144:1591; Mustelin et al., *Science* 1990, 247:1584). Because TCR dependent  $Ca^{2+}$  flux was impaired, TCR-dependent protein tyrosine phosphorylation  
30 was also investigated and found to be altered. The basal

pattern of protein tyrosine phosphorylation was altered in T cells from tumor-bearing mice as compared to normal cells.

TCR-mediated signalling was determined in T lymphocytes from tumor-bearing mice. (A) TCR-dependent  $\text{Ca}^{2+}$  mobilization was determined as follows: T cells ( $1 \times 10^7$ ) were loaded with Indo-1 and stimulated with anti-CD3 ( $1 \mu\text{g/ml}$ ). Maximal  $\text{Ca}^{2+}$  release was determined in cells stimulated with calcium ionomycin. Maximal fluorescence was determined in cells lysed with Triton-X 100 and minimum fluorescence was measured after chelation of  $\text{Ca}^{2+}$  with EGTA. The concentration of free intracellular  $\text{Ca}^{2+}$ ,  $[\text{Ca}^{2+}]_i$ , was measured by methods taught in Grynkiewicz et al. *Biol. Chem.*, 260: 3440 (1985). (B) Protein tyrosine phosphorylation was determined as follows: Purified T cells ( $10 \times 10^6$ ) from normal (N) or tumor-bearing (T) mice were stimulated (+) or left untreated (-) in serum-free medium with  $10 \mu\text{g/ml}$  of purified anti-CD3 for 2 min. The reaction was terminated by washing the cells twice in ice-cold phosphate-buffered saline containing  $400 \mu\text{M}$  sodium orthovanadate and  $1\text{mM}$  EDTA. The T cells were lysed and centrifuged to remove nuclei. Proteins in supernatants were separated by SDS-PAGE, transferred to Immobilon P filters (Millipore), and immunoblotted with antibody to phosphotyrosine, MAb-4G10 ( $40 \text{ ng/ml}$ ). (C) Expression of  $\text{p}56^{\text{Lck}}$  and  $\text{p}59^{\text{Fyn}}$  in T lymphocytes from normal and tumor-bearing mice was determined as follows: Proteins in cell lysates were separated by SDS-PAGE (14% gel), transferred to Immobilon

P, and immunoblotted with antiserum to Lck and Fyn peptides (UBI).

Stimulation with anti-CD3 did induce protein tyrosine phosphorylation, but the pattern of proteins phosphorylated was not normal. The abnormal pattern of basal protein tyrosine phosphorylation in these T cells may have resulted from alterations in the expression of cellular protein tyrosine kinases or in the synthesis of the substrates. Therefore, expression of p56<sup>lck</sup> and p59<sup>fyn</sup> two Src family protein tyrosine kinases (PTKs) expressed in T lymphocytes (Varonova and Sefton, 1986, Nature 319:682; Rudd et al., P.N.A.S. 1988, 85:5190; Samuelson et al., 1990, P.N.A.S. 87:4358), was assessed. Immunoblotting of proteins from whole cell extracts demonstrated a reduction in p56<sup>lck</sup> and p59<sup>fyn</sup> in T cells from tumor-bearing mice as compared to normal mice.

Consistent with this altered pattern of phosphorylation in T lymphocytes from late TBM, the expression of Lck in these same cells was markedly decreased. A sample cell lysate, prepared as described above, was run in an 8% SDS-PAGE and blotted with anti-Lck or anti-Fyn rabbit serum. The absence of  $\zeta$  and the reduction in Lck may alter the signal transduction process, thereby preventing or delaying the activation of the lytic mechanism. Changes in the level of expression in T lymphocytes of  $\zeta$ , CD3 $\gamma$  and Lck provide markers with which to identify cells capable of activation for adoptive immunotherapy.



In addition to the structural changes in the TCR, the T cells from tumor-bearing mice have a decrease in p56<sup>lck</sup> and p59<sup>fyn</sup>. Studies with PTK inhibitors have demonstrated the function of such enzymes in TCR-mediated signal transduction (June et al., 1980 loc. cit.). However, proliferation in response to anti-CD3, up-regulation of interleukin-2 receptors, and production of lymphokines (interleukin-2, interleukin-6, interferons) remained normal in T cells from tumor-bearing mice. Thus, lytic function may be more dependent on PTK activity than other lymphocyte functions. Interleukin-2 secretion can be normal in the absence of TCR dependent Ca<sup>2+</sup> flux.

Supernatants from a variety of tumor cell lines inhibit anti-CD3-induced cytotoxicity by normal T cells in vitro. Precisely the same functional abnormalities and TCR structural abnormalities are observed in T cells from BALB/c mice bearing the RENCA renal cell adenocarcinoma. Thus, these findings are not unique to MCA-38 bearing mice. These findings are likely to be related to the interaction of the tumor and the host in these animals. The molecular changes described herein occur during stages of the disease in both MCA-38- and RENCA-bearing mice when mice are not cachectic or moribund.

25

#### Example 12

##### **Expression of TCR Subunits**

The structure of the TCR was evaluated by surface iodination of purified T cells from normal and tumor-bearing mice. Proteins in the TCR complex were then

immunoprecipitated with anti-CD3 and separated by two-dimensional, nonreducing-reducing SDS-polyacrylamide gel electrophoresis (PAGE) (Samuelson et al., 1985 Cell, 43:223).

5           Alterations in the structure of the TCR in T lymphocytes from tumor-bearing mice were determined as follows: Fifty million T lymphocytes were labeled with  $\text{Na}^{125}\text{I}$  by the lactoperoxidase-glucose oxidase method. After labeling, cells were lysed in 1 ml of lysis buffer  
10 [25 mM Tris (pH 7.4), 300 mM NaCl, 0.5% Triton X-100, 1mM sodium orthovanadate, 10  $\mu\text{g/ml}$  aprotinin, 10  $\mu\text{g/ml}$  leupeptin and 5 mM EDTA] for 5 min on ice. The TCR complexes were immunoprecipitated from supernatants of cell lysates with anti-CD3 adsorbed to protein G-  
15 sepharose and resolved by 2-dimensional non-reducing (NR)-reducing (R) SDS-PAGE (14% gel). The specificity of the subunits immunoprecipitated was confirmed with a cell line (BW5147) that lacks the TCR. Immunoblot analysis of TCR  $\zeta$  and Fc $\epsilon\gamma$  expression were performed as follows: T  
20 cells ( $20 \times 10^6$ ) from normal, tumor-bearing mice, BW5147, and 2B4.11 were solubilized and proteins from supernatants of cell lysates were immunoprecipitated with rabbit antiserum to CD3 $\zeta$  (387) or normal rabbit serum (NRS). Lysates from TCR negative BW5147 thymoma were  
25 used. The 2B4.11 hybridoma was used as positive control for Fc $\epsilon\gamma$ . Proteins in immunoprecipitates were blotted with rabbit antiserum to CD3 $\zeta$  peptide (387) (provided by R. Klausner, NICHD) and antiserum to Fc $\epsilon\gamma$  (provided by J.P. Kinet, NIAID). Blots were developed with

peroxidase-conjugated monoclonal antibody to mouse IgG by enhanced chemiluminescence (Amersham).

Both the TCR $\alpha\beta$  heterodimer (which migrated below the diagonal because of interchain disulfide bonds) and CD3 $\epsilon$ -chain (which migrated above the diagonal because of intrachain disulfide bonds) were present in approximately normal amounts in T lymphocytes from tumor-bearing mice.

In contrast, alterations in other elements of the TCR-CD3 complex were apparent in T cells from tumor-bearing mice. The CD3 $\zeta$ -chain was absent and the amount of CD3 $\gamma$ -chain was reduced. The failure to detect the  $\zeta$ -chain in association with the TCR expressed on the cell surface might result from reduced steady state amounts of CD3 $\zeta$ , aberrant assembly and transport, or instability of detergent solubilized receptor complexes. To determine if detectable levels of CD3  $\zeta$  protein were present, proteins were immunoblotted from whole cell lysates of splenic T cells. Again, in contrast to normal T cells, the CD3  $\zeta$ -chain was absent from T cells of tumor-bearing mice. This result was paradoxical because the TCR is transported to the cell surface inefficiently in the absence CD3 of  $\zeta$ -chain (Sussman et al., 1989). However, the TCR can be associated with other  $\zeta$  family members (Orloff et al., 1990). The Fc $\epsilon\gamma$ -chain is a  $\zeta$ -related protein that subserves  $\zeta$ -like function in Fc receptor assembly and transport and in signal transduction (Reth, 1989). A protein of smaller molecular size than the  $\zeta$ -chain was present in the surface labeling experiment that was similar in size to Fc $\epsilon\gamma$ . The presence of this

chain in tumor-bearing T cells was confirmed by immunoblotting with antibody to Fc $\epsilon$  $\gamma$  (anti-Fc $\epsilon$  $\gamma$ ). Thus, the T lymphocytes from tumor-bearing mice expressed unusual TCR complexes that lacked the CD3 $\zeta$ -chain, but  
5 contained the Fc $\epsilon$  $\gamma$ -chain in the majority of T cells. Abnormal TCR complexes were noted in both CD4<sup>+</sup> and CD8<sup>+</sup> subsets. The steady state levels of mRNA for lck and CD3 $\zeta$  chain were normal or elevated suggesting that the defect may be at the post-transcriptional level.

Example 13**Assays for Proteins of the TCR subunits and T Lymphocyte Signal Transduction Pathway After Treatment of Tumors with Flavonoids and IL-2**

5           Certain forms of cancer remain invulnerable to attack  
by therapeutic regimes. For example, renal cell  
carcinoma (adenocarcinoma) is resistant to conventional  
chemotherapy. This is a devastating disease because many  
patients have metastatic disease by the time of  
10          diagnosis. Therefore, most of the methods of treatment  
are ineffective against renal cell carcinoma, although  
some anti-tumor effects have been observed using  
biological response modifiers (BRM). Because some  
biological response modifiers used individually ( $\alpha$ -IFN,  
15          IL-2) showed therapeutic efficacy at least as good as  
conventional chemotherapy, combined modality approaches,  
including BRM/BRM and BRM/chemotherapy, were pursued to  
improve efficacy.

          Rodent models are useful in identifying  
20          therapeutically effective combinations of treatment  
modalities. Complex experiments involving various  
permutations in potential therapeutic agents, dose, and  
administration schedule, may be performed quickly,  
relatively inexpensively, and without risk to patients.  
25          An example of a rodent model is the RENCA system, wherein  
a RENCA renal adenocarcinoma of Balb/c origin is  
implanted in an orthotropic site, from which it  
metastasizes, Murphy and Hrushesky, *J. Natl. Cancer*  
*Inst.*, 50: 1013 (1980).

Most cytokines are ineffective when used as single agents. The most effective experimental treatments for this tumor include IL-2 in the protocol. Specifically, the use of IL-2 in combination with IFN or cytokine-inducing flavonoids has proved most effective.

In animals that showed tumor reduction, T cells were found to be essential for the anti-tumor response. Moreover, changes in signal transduction molecules associated with tumors, were reversed by therapy. The altered T-cell tyrosine phosphorylated pattern returned to normal, as shown by Western blots. Re-expression of lck and zeta occurred as early as 7 weeks after tumor injection (3-4 weeks after treatment.) TCR and the CD3 complex were not altered.

15

#### Example 14

##### **Evaluation of Patients for Adaptive Immunotherapy.**

A patient having renal carcinoma is selected and a lymphocyte preparation is made from peripheral blood to be analyzed for the expression of CD3 $\zeta$  protein. Lymphocytes are obtained from a healthy individual and prepared and analyzed in the same manner. Peripheral blood lymphocytes are isolated by venipuncture or lymphopheresis. The cells are separated on a Ficoll-Hypaque gradient to obtain mononuclear cells. The cell density of the mononuclear cells thus obtained is determined and equal numbers of cells from the patient and the healthy individual are extracted for protein.

25

Equal numbers of cells are solubilized in lysis

buffer (25 mM Tris pH7.4, 150 mM NaCl, 0.5% Triton-X 100, 1 mM sodium orthovanadate, 10 $\mu$ g/ml aproptinin, 10  $\mu$ g/m; leupeptin and 5 mM EDTA). The lysate is centrifuged and the supernatant is immunoprecipitated with rabbit anti- $\zeta$  antiserum. A control lysate is immunoprecipitated with normal rabbit serum. Immunoprecipitate is resolved by SDS-PAGE, transferred to Nylon membrane (Imobilon-P), and blotted with anti- $\zeta$  rabbit serum. A marked reduction in the expression  $\zeta$  protein in the patient, as compared to the control, is diagnostic of immunosuppression and loss of the ability to use the patient's T lymphocytes in autologous adoptive immunotherapy.

#### Example 15

##### **Protein Expression Changes in Patients with Cancer**

In seven of twelve human cancer patients, peripheral blood T cells were found to lack or have decreased expression of the CD3 $\zeta$  chain. Some had a decreased expression of Lck and PLC $\gamma$ . Thus, structural and functional alterations are also noted in T cell signal transduction molecules from tumor-bearing humans.

#### Example 16

##### **Vaccines**

In another embodiment, the immunosuppressive factor of the present invention is used in a pharmaceutically acceptable composition that, when administered in an effective amount, is capable of including protective immunity against immunosuppression.

The preparation of vaccines which contain proteins

as active ingredients is well understood in the art. Typically, such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to inject may also be prepared. The preparation may also be emulsified. The active immunogenic ingredient is often mixed with excipient which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents or adjuvants or immunopotentiators which enhance the effectiveness of the vaccine.

The vaccines conventionally are administered parenterally or by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations. For suppositories, traditional binders and carriers may include, for example, polyalkylene glucose or triglycerides; such suppositories may be formed for mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1.2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of saccharine, cellulose, magnesium carbonate and the like. The compositions take the form of solutions, suspension,



tablets, pills, capsules, excipient which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents or adjuvants or immunopotentiators which enhance the effectiveness of the vaccine.

10       The proteinaceous particles can be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts, include the acid addition salts (formed with the free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

25       The term "unit dose" refers to physically discrete units suitable as unitary dosages for humans, each unit containing a predetermined-quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier, or vehicle.

The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective and immunogenic. The quantity to be administered depends on the subject to be treated, capacity of the subject's immune system to synthesize antibodies, and degree of protection desired. Precise amounts of active ingredients required to be administered depend on the judgement of the practitioner and are peculiar to each individual. However, suitable dosage ranges are of the order of one to several hundred micrograms active ingredient per individual. Suitable regimens for initial administration and booster shots are also variable, but are typified by an initial administration followed in one or two week intervals by a subsequent injection or other administration.

#### EXAMPLE 17

##### **Diagnostic Systems (Kits)**

A diagnostic system, preferably in kit form, useful for detecting the presence of a protein of the present invention protein or antibodies to the protein in a body sample, includes in separate packages, (a) a protein of the present invention which displays antigenicity, and (b) a labeled specific binding agent for signaling the presence of the immunoreaction of the protein of the present invention with antibodies.

A "specific binding agent" is a molecular entity capable of selectively binding a ligand such as a protein of the present invention or an antibody that immunoreacts with a protein of the present invention. Exemplary

specific binding agents are antibodies or antibody fragments such as Fab' and F(ab')<sub>2</sub>, complement fragments, protein A and the like.

In this description, the term "label" in its various grammatical forms refers to single atoms and molecules that are either directly or indirectly involved in the production of a detectable signal to indicate the presence of a immunoreactant. Any labeling means can be linked to, or incorporated in, a specific binding agent or used separately, and those atoms or molecules can be used alone or in conjunction with additional reagents. Such labels are themselves well-known in immunochemistry and constitute a part of this invention only insofar as they are utilized with otherwise novel proteins methods and/or systems.

The diagnostic kits of the present invention are typically used in an "ELISA" format to detect the presence of quantity of antibodies in a body sample such as serum or plasma. "ELISA" refers to an enzyme-linked immunosorbent assay that employs an antibody or antigen bound to a solid phase and an enzyme-antigen or enzyme-antibody conjugate to detect and quantify the amount of antigen or antibody present in a sample. A description of the ELISA technique is found in Chapter 22 of BASIC AND CLINICAL IMMUNOLOGY (4th ed. 1982) by D.P. Sites et al., published by Lange Medical Publications of Los Altos, California, and in U.S. Patent Nos. 3,654,090, No. 3,850,752 and No. 4,016,043, the respective contents of which are incorporated herein by reference.

Thus, in preferred embodiments the protein displaying antigenicity is affixed to a solid matrix to form a solid support. Typically, the protein can be affixed to the solid matrix by adsorption from an aqueous medium  
5 although several modes of adsorption from an aqueous medium as well as other modes of affixation, well known to those skilled in the art can be used. Exemplary of such modes are the reaction of the receptor or antigen with the reactive carboxyl functionality produced by the  
10 reaction of cyanogen bromide with glucose-containing matrices such as cross-linked dextrose or cellulose, glutaraldehyde linking as discussed hereinafter in conjunction with latex particles and the like.

Useful solids are well known in the art. Such  
15 materials include the cross-linked dextran available under the trademark SEPHADEX from Pharmacia Fine Chemicals (Piscataway, NJ); agarase; beads of polystyrene beads about 1 micron to about 5 millimeters in diameter available from Abbott Laboratories of North Chicago, IL;  
20 polyvinyl chloride, polystyrene, cross-linked polyacrylamide, nitrocellulose or nylon-based webs such as sheets, strips or paddles; or tubes, plates or the wells of a microtiter plate such as those made from polystyrene or polyvinylchloride.

25 In a preferred embodiment, the kit further includes, in a separate package, an amplifying reagent such as complement, like guinea pig complement, anti-immunoglobulin antibodies or *S. aureus* cowan strain protein A that reacts with the antigen or antibodies

being detected. In these embodiments, the label specific binding agent is capable of specifically binding the amplifying means when the amplifying means is bound to the protein or antibody.

5       The label specific binding agent of any diagnostic system described herein, as well as the above-described amplifying reagent, may be provided in solution, as a liquid dispersion or as a substantially dry powder, for example, in lyophilized form. Where the indicating means  
10       is an enzyme, the enzyme's substrate can also be provided in a separate package of the system. A solid support such as a microtiter plate and one or more buffers can also be included as separately packaged elements in this diagnostic assay system.

15       The packages discussed herein in relation to diagnostic systems are those customarily utilized in diagnostic system. Such packages include glass and plastic (e.g., polyethylene, polypropylene and polycarbonate) bottles, vials, plastic and plastic-foil  
20       laminated envelopes and the like.

#### EXAMPLE 18

**The Pattern of NF- $\kappa$ B/rel Transcription Factors is Altered in an Animal Tumor Model, and Reversed by Therapy**

25       An impaired immune system has been documented both in a cancer patient and in tumor-bearing mice. Among the contributing factors for the immune impairment, T-cell function plays an important role. In order to investigate the T-cell condition in a tumor bearing  
30       mammal, a spontaneously arising renal cell carcinoma

(Renca) model from a BALB/c mouse was used. This tumor model has two important features: (1) the metastatic pattern displayed by Renca is similar to human renal cell carcinoma, Golumbek et al. (1991) "Treatment of  
5 Established Renal Cancer by Tumor Cells and Engineered to Secrete Interleukin-4" and (2) it has been shown in this murine model that the experimental drug Flavone-8-acetic acid (FAA) in combination with rIL-2 cures 80% of mice bearing established Renca tumors, and that these mice  
10 have successfully responded to subsequent rechallenge. Wiltrout et al. (1988) "Flavone-8-Acetic Acid Augments Systemic Natural Cell Activity and Synergizes with IL-2 for the Treatment of Murine Renal Cancer," (1988) *J. Immunol.* 140(9):3261

15 When nuclear extracts of normal splenic T-cells were examined in Western blot analysis using anti-c-rel, anti-p65, and anti-p50 antisera, normal levels of all three proteins were observed. In contrast, nuclear extracts of splenic T-cells from tumor-bearing mice were devoid of c-rel and p65. Unexpectedly, in place of p50, two shorter  
20 forms of the protein (p48 and p44), where "48" and "44" refer to estimated approximate molecular weights of 48 and 44kD respectively, as determined by gel electrophoresis, were observed in the nucleus.

25 The specificity of antisera against c-rel, p65 and p50, was demonstrated by competition with the respective peptides. Although the shorter forms of p50 were present exclusively in the nucleus, normal sized protein was present in the cytoplasm. When the same extracts were

analyzed for p50 using an antiserum made against an N-terminal peptide of the protein, no shorter form of p50 was detected, although this antiserum was able to detect normal p50. The interpretation of these results is that the shorter forms of p50 are due to the N-terminal truncation of the protein. These new forms of p50 could also result from alternate splicing, although no shorter form of the precursor molecule, p105, was observed in the cytoplasmic fraction of the tumor sample.

10 In order to determine whether absence of nuclear c-rel and p65, and presence of alternate forms of p50 in splenic T-cells from tumor-bearing mice correlated with the presence of a tumor, splenic T-cells from FAA/IL-2-treated animals sampled at various time points after treatment, were analyzed by Western blot. Treatment of tumor-bearing mice with FAA was initiated at 7 days. IL-2 was administered on each of days 8-10 days. Eleven days later, splenic T-cells showed the same pattern as an untreated tumor-bearing group of mice with respect to nuclear c-rel, p65 and p50. In contrast, splenic T-cells from animals treated with FAA and IL-2 for another week showed approximately normal levels of nuclear c-rel, p65 and p50. Interestingly, shorter forms of p50 were no longer present in the treated group. No sign of visible tumor was observed either by macroscopic or microscopic analysis in treated animals four weeks after tumor initiation, that is, three weeks after treatment. The untreated tumor-bearing group normally dies at about day 35. Analysis of splenic T-cells from mice exhibiting

long term survival, defined as surviving to week 7, showed that the nuclear levels of rel family members were normal.

When the nuclear extracts of splenic T-cells from normal and tumor-bearing animals were used in an electrophoretic mobility shift assay (EMSA) Tan, T.H. et al. , "Purification and characterization of multiple nuclear factors that bind to the TAX-inducible enhancer within the human T-cell leukemia virus type 1 long terminal repeat." (1989) *Mol. Cell. Biol.* using an oligonucleotide from an immunoglobulin heavy chain gene, the patterns of DNA-protein complexes differed in tumor samples compared to non-tumor bearing samples. As compared to the normal pattern, two faster migrating complexes were observed. Both of these complexes were specific to the nucleotide probe as revealed by competition analysis with specific and non-specific oligonucleotides. These new DNA-protein complexes also correlated with the status of the tumor, as revealed by the reappearance of the normal pattern in samples from the group assessed four weeks after tumor initiation.

In order to characterize the nature of the DNA-protein complexes in tumor samples, UV-crosslinking Kochel et al., "V-rel and C-rel-Protein Complexes Bind to the NF- $\kappa$ B site *In Vitro*," *Oncogene* (1992) 7:567-572 and immunoprecipitation, Rice et al. (1992) *Cell*, 71:243-263, of the crosslinked product were performed. In a normal sample, the slower migrating DNA-protein complex consisted of two proteins corresponding to a combination



of a p50 and p65, whereas the faster migrating complex consisted of a protein corresponding to p50, as has been shown before Sang-Mo Kang et al., "NF- $\kappa$ B Subunit Regulation in Nontransformed CD4+T Lymphocytes" (1992) Science 256: 1452. In a tumor sample, the upper DNA-protein complex consisted of a protein which was shorter than p50, and the lower complex consisted of two proteins corresponding to two shorter derivatives of p50. UV-crosslinked products were immunoprecipitated with different anti-p50 antisera. When immunoprecipitation was done with normal samples, the slower migrating complex was found to be precipitated with two different anti-p50 and one anti-p65 antiserum. These results indicated that the upper complex consisted of p50 and p65. The faster migrating complex was found to be precipitated by three different anti-p50 antisera, which indicated that the lower complex consisted of p50.

When tumor samples were analyzed, the slower migrating complex was found to be precipitated by two different anti-p50 antisera, but not by the third antiserum which was made against the N-terminal peptide. Based on the molecular weight of the precipitated molecule, it was concluded that the upper complex consisted of p48. Similarly, the faster migrating complex was found to be precipitated by the same two anti-p50 antisera as in the upper complex, but not by the antiserum made against the N-terminal peptide. In this case, two proteins were obtained that correspond to p48 and p44, corresponding to the anti-peptide antisera. No

protein band was obtained when immunoprecipitation was done with preimmune sera.

## MATERIALS AND METHODS

### Stimulation of T Lymphocytes

5        In an illustrative embodiment, T lymphocytes are stimulated with an antibody to a lymphocyte surface receptor *in vitro*, for short time periods. Optionally, one or more cytokines also are present during stimulation. The time periods for stimulation are less  
10        than about 24 hours, for as little as 30 minutes, and generally for 12-18 hours. These stimulated cells have a high therapeutic efficacy when injected *in vivo*. Stimulation by anti-CD3 induces the expression of the IL-2 receptor. Anti-CD3-stimulated cells are less toxic  
15        than cells cultured in IL-2 for several days because the anti-CD3-stimulated cells cause less acute pulmonary toxicity. Similarly, because anti-CD3 stimulated cells can multiply in number in the presence of IL-2, small numbers of injected anti-CD3 stimulated cells can  
20        proliferate to large numbers following *in vivo* exposure to IL-2. Thereby, fewer cells need to be administered when IL-2 is present, to achieve sufficient numbers of anti-CD3 stimulated cells.

          Alternatively, T lymphocytes are stimulated *in vitro*  
25        with antibodies directed to more than one lymphocyte surface receptor. Optionally, one or more cytokines are also be present during stimulation. The stimulation of T lymphocytes *in vivo* can also be accomplished with antibodies to one or more T lymphocyte surface receptors;

with one or more cytokines; or with a combination of antibodies and cytokines.

### Kinase Reaction Assay

- Lyse  $10^7$  cells in a standard manner
- 5 Immunoprecipitate with anti-Fyn Ab ( $6, \mu\text{l}$ ) or anti-Lck Ab ( $3 \mu\text{l}$ )
- Wash 3X with washing buffer without EDTA
- Wash 1X kinase buffer without ATP
- Add  $30 \mu\text{l}$  of kinase buffer plus  $10\text{--}20 \mu\text{Ci}$  of  $[\gamma\text{-}^{32}\text{P}]\text{ATP}$  ( $3300\text{Ci}/\text{mmol}$ ) ( $3\text{--}5 \mu\text{l}$ ) and  $1 \mu\text{M}$  ATP
- 10 Incubate R/T for 10 min.
- Wash 3X with washing buffer containing  $20\text{mM}$  EDTA
- Elute  $1.5\text{X}$  sample buffer
- Run 8% of gel
- 15 Fix the gel in 10% AcAcid and 50% MTOH for 30 min.
- Replace with 3% glycerol for 20 min.
- Dry up the gel using the gel dryer for 1.5 hr.
- Expose the gel to X-ray film
- \* Kinase Buffer
- 20 100 mM NaCl  
20 mM HEPES, pH 7.5  
5 mM  $\text{MnCl}_2$   
5 mM  $\text{MgCl}_2$
- 25 

---

1  $\mu\text{M}$  ATP  
3-5  $\mu\text{l}$  of  $[\gamma\text{-}^{32}\text{p}]\text{ATP}$

### Methods for Producing Antibodies

An antibody to a T lymphocyte surface receptor protein or to the soluble immunosuppressive factor can be made by well known and conventional methods, for example  
5 those described in Current Protocols in Immunology, Vol. I, J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach and W. Strober (eds.), Green Publishing Associates and Wiley-Interscience, 2.4.1-2.10.3 (1991), which is incorporated herein by reference.

10 A monoclonal antibody is prepared which is directed toward the factor. The antibody is developed using supernatants from tumor preparations as an immunogen, and techniques known to those of skill in the art. The monoclonal antibody is useful in purifying the factor by  
15 affinity chromatography (Marlow and Lane Antibodies Manual).

Antibodies to a surface receptor are used alone, or in combination with other antibodies to different T cell surface receptors to activate T lymphocytes. Suitable  
20 antibodies include anti-CD2, anti-CD3, anti-CD4, anti-CD5, anti-CD6, anti-CD7, anti-CD8, anti-CD28, anti-CDw29, and anti-CD45R. A preferred antibody is anti-CD3 monoclonal antibody (MAb). An anti-CD3 MAb includes OKT3, WT32, Leu-4, SPV-T3c, RIV9, 64.1, 145-2C11, and the  
25 like. More preferably, the anti-CD3 MAb is the anti-murine CD3 MAb 145-2C11, which has been identified by Leo et al, Proc. Natl. Acad. Sci. USA, 84, 1374 (1978), and is available from the American Type Culture Collection

(ATCC). Mouse anti-human OKT3 is available from the Ortho Division of Johnson and Johnson. Versions of the antibodies derived from humans are useful for T cell activation *in vivo* during treatment. T lymphocytes  
5 treated with anti-CD3 MAb for less than about 24 hours are preferably treated with a total dose of about 10/ng/ml, or less.

**Isolation and Purification of the Soluble  
Immunosuppressive Factor**

10 The immunosuppressive factor is purified from supernatants of tumor cell preparations by sequential gel filtration, anion and cation exchange, and FPLC. These methods are known to those of skill in the art. The final purification steps may require HPLC using ion  
15 exchange or reverse phase chromatography. Polypeptide fragments of the isolated factor are tested to determine which fragments retain the immunosuppressive activity. The amino acid sequences of those polypeptide fragments are determined. Degenerate oligonucleotides are then  
20 derived from the amino acid sequences and used to clone the factor using techniques described by Maniatis (1982). (Molecular Cloning, a Laboratory Manual, Cold Spring Harbor, New York).

What Is Claimed Is:

1. A soluble immunosuppressive factor having the following properties:

5 a) capable of effecting a decrease in the level of a TCR subunit protein in a biological specimen from a mammal in comparison with the level of the subunit in a comparable biological specimen from a non-immunosuppressed mammal;

10 b) capable of effecting a decrease in the level of a T-lymphocyte signal transduction pathway protein in a biological specimen from a mammal in comparison with the level of the protein in a comparable biological specimen from a non-immunosuppressed mammal; and

15 c) present in serum derived from an immunosuppressed mammal.

2. The factor of claim 1 further defined as present in the supernatant of a tumor cell culture.

3. The factor of claim 2 wherein the tumor cell culture is the MCA-38 line or the MBL-2 lymphoma.

20 4. The factor of claim 3 wherein the immunosuppressed mammal is a mouse having a tumor of the MCA-38 line present for about 26 days or more.

5. The factor of claim 1, wherein the TCR subunit protein is CD3 $\delta$ .

25 6. The factor of Claim 1, wherein the TCR subunit protein is CD3 $\gamma$ .

7. The factor of claim 1, wherein the T-lymphocyte signal transduction pathway protein is a tyrosine kinase of the Src family.

8. The factor of claim 7, wherein the tyrosine kinase of the Src family is Fyn or lck.

9. The factor of claim 1, wherein the signal transduction protein is PLC $\gamma$  or GAP.

5 10. A method of determining the level of immunosuppression in a sample of mammalian cells, said method comprising the steps of:

a) determining the level of expression of a TCR subunit protein or a protein in the T lymphocyte signal  
10 transduction pathway; and

b) comparing said level of protein expression with the level of expression of said protein characteristic of non-immunosuppressed individuals of the same mammalian species.

15 11. The method of claim 10, wherein the sample of mammalian cells is a lymphocyte preparation.

12. The method of claim 10, wherein the level of expression is measured as an expression ratio, defined as the ratio of the number of T lymphocytes expressing said  
20 protein to the total number of T lymphocytes counted.

13. The method of claim 11, wherein said lymphocyte preparation is prepared from tissue comprising spleen tissue, peripheral blood, tumor tissue, lymph node tissue, cerebrospinal fluid, pleural effusions and  
25 ascites.

14. The method of claim 10, wherein said TCR subunit protein comprises CD3 $\zeta$ .

15. The method of claim 10, wherein said signal transduction pathway protein comprises a tyrosine kinase of the src family.

16. The method of claim 15 wherein the tyrosine  
5 kinase is Fyn or lck.

17. The method of claim 10, wherein the signal transduction pathway protein is PLC $\gamma$  or GAP.

18. A method of identifying a patient having T lymphocytes capable of activation for immunotherapy, said  
10 method comprising the steps of:

a) determining the level of expression of a TCR subunit protein or a protein in the T lymphocyte signal transduction pathway;

b) comparing said level of protein expression with  
15 the normal level of expression of said protein characteristic of non-immunosuppressed individuals; and

c) selecting a patient whose level of expression of said protein is above a therapeutically effective threshold in non-immunosuppressed individuals.

20 19. The method of claim 18, wherein said level of expression is measured as an expression ratio, defined as the ratio of the number of T lymphocytes expressing said protein to the total number of T lymphocytes counted.

20. The method of Claim 18, wherein said level of  
25 expression is defined as the amount of said protein per microgram of total protein isolated from a lymphocyte preparation.

21. The method of claim 18, wherein said T lymphocytes are derived from tissue comprising spleen



tissue, peripheral blood, tumor tissue, lymph node tissue, cerebrospinal fluid, pleural effusions and ascites.

22. The method of claim 18, wherein said TCR subunit  
5 comprises the protein CD3 $\zeta$ .

23. The method of claim 18, wherein said signal transduction pathway protein comprises a tyrosine kinase of the Src family.

24. The method of claim 23, wherein the tyrosine  
10 kinase of the src family is Fyn or lck.

25. The method of claim 18, wherein the signal transduction pathway protein is PLC $\gamma$  or GAP.

26. In a method of treating a patient who has a disease responsive to immunotherapy, wherein said patient  
15 is treated with stimulated T lymphocytes, the improvement wherein said patient is identified by the method according to claim 18.

27. The method of claim 26, wherein said disease is cancer.

28. The method of claim 27 wherein said cancer is  
20 melanoma.

29. A method of identifying an agent which causes immunosuppression of mammalian T lymphocytes, said method comprising the steps of:

25 a) providing a mammalian T lymphocyte preparation wherein the level of expression of a TCR subunit protein or a protein in the T lymphocyte signal transduction pathway is comparable to levels characteristic of non-

immunosuppressed individuals of the same mammalian species;

b) culturing said lymphocyte preparation in the presence of a suspected immunosuppressive agent;

5 c) determining the level of expression of said selected protein; and

d) identifying an agent which causes a significant reduction below the level of expression of said protein in a T lymphocyte preparation not cultured in the presence of the agent.

10

30. A method of identifying an agent which reverses immunosuppression of mammalian T lymphocytes, said method comprising the steps of:

a) providing a mammalian T lymphocyte preparation from an immunosuppressed mammal, wherein the level of expression of a TCR subunit protein or a protein in the signal transduction pathway is below the level of non-immunosuppressed individuals of the same mammalian species;

15

b) culturing said lymphocyte preparation in the presence of an agent suspected of reversing immunosuppression;

20

c) determining the level of expression of said selected protein in the culture; and

d) identifying an agent which causes a significant increase in the level of expression of said protein.

25

31. The method of Claim 30, wherein the agent is present *in vivo*.

32. A method to screen for an agent that inhibits a soluble immunosuppressive factor, said method comprising:

a) adding the agent to a cellular system that  
5 contains the factor of Claim 1;

b) determining the level of immunosuppression in the system by:

i) determining the level of expression of a TCR subunit protein or a protein in the T lymphocyte signal  
10 transduction pathway and

ii) comparing said level of protein expression with the level of expression of said protein characteristic of non-immunosuppressed individuals of the same mammalian species; and

15 c) determining whether the system exhibits a reversal of immunosuppression.

33. A method of treating an immunosuppressed mammal by administering a therapeutically effective amount of an agent identified in claim 30 in a pharmaceutically  
20 acceptable diluent.

34. The method of claim 33 wherein the mammal is a human.

35. An antibody directed against the immunosuppressive factor of claim 1 or a epitopic portion  
25 thereof.

36. An agent that inhibits the factor of claim 1.

37. The agent of claim 36 comprising anti-CD3 and IL2.

38. An antisense construct directed against the expression of the factor of claim 1.

39. A gene encoding the factor of claim 1.

40. A vaccine comprising the factor of claim 1.

5        41. A kit for monitoring immunosuppression, said kit comprising in a separate container an antibody directed against a TCR subunit protein or a signal transduction pathway protein, and means for detecting the formation of an antibody-antigen complex.

10       42. Mammalian cells treated with the soluble factor of Claim 1.

43. A method of treating a mammal with the factor from Claim 1 to induce immunosuppression necessary for inducing autoimmunity or facilitating organ  
15 transplantation by administering to the mammal an effective amount of factor in a pharmaceutically acceptable carrier.

44. A method of treating an immunosuppressed mammal be administering a therapeutically effective amount of an  
20 agent identified in claim 32 in a pharmaceutically acceptable diluent.

45. A method of determining the level of immunosuppression in a mammal, said method comprising the steps of:

25        a) determining the pattern of transcription factors of the NF- $\kappa$ B/rel family in a nuclear extract of a sample of cells from a mammal; and

      b) comparing said pattern with the pattern characteristic of a comparable cell sample from a non-  
30 immunosuppressed individual of the same mammalian species, a significant departure from the pattern in the

non-immunosuppressed individual indicating a significant degree of immunosuppression in the mammal.

46. The method of claim 45, wherein the sample of mammalian cells is a lymphocyte preparation.

5        47. The method of claim 45, wherein the pattern is determined by presence or absence of c-rel, p65, p50, p48 and p44.

10       48. The method of claim 46, wherein said lymphocyte preparation is prepared from tissue comprising spleen tissue, peripheral blood, tumor tissue, lymph node tissue, cerebrospinal fluid, pleural effusions and ascites.

15       49. A method of identifying a patient having T lymphocytes capable of activation for immunotherapy, said method comprising the steps of:

      a) determining the pattern of transcription factors of the NF- $\kappa$ B/rel family in a nuclear extract of T lymphocytes from the patient;

20       b) comparing said pattern with the pattern characteristic of a non-immunosuppressed individual; and

      c) selecting a patient whose pattern is above a therapeutically effective threshold in a non-immunosuppressed individual.

25       50. The method of claim 49, wherein said T lymphocytes are derived from tissue comprising spleen tissue, peripheral blood, tumor tissue, lymph node tissue, cerebrospinal fluid, pleural effusions and ascites.

30       51. In a method of treating a patient who has a disease responsive to immunotherapy, wherein said patient is treated with stimulated T lymphocytes, the improvement wherein said patient is identified by the method according to claim 49.

35       52. The method of claim 51, wherein said disease is cancer.

      53. The method of claim 52 wherein said cancer is melanoma.

54. A method of identifying an agent which causes immunosuppression of mammalian T lymphocytes, said method comprising the steps of:

5 a) providing a mammalian T lymphocyte preparation wherein the pattern of transcription factors of the NF- $\kappa$ B family in a nuclear extract of the sample is characteristic of a non-immunosuppressed individual of a mammalian species;

10 b) culturing said lymphocyte preparation in the presence of a suspected immunosuppressive agent;

c) determining the pattern of transcription factors of the NF- $\kappa$ B family in a nuclear extract of the cultured preparation; and

15 d) identifying an agent which causes a significant alteration in the pattern from the pattern of the preparation not cultured in the presence of the agent.

55. A method of identifying an agent which reverses immunosuppression of mammalian T lymphocytes, said method comprising the steps of:

20 a) providing a mammalian T lymphocyte preparation from an immunosuppressed mammal, wherein the pattern of the transcription factors of the NF- $\kappa$ B family in a nuclear extract of the preparation is significantly altered from the pattern characteristic of a comparable sample from a non-immunosuppressed individual of the same mammalian species;

25 b) culturing said lymphocyte preparation in the presence of an agent suspected of reversing immunosuppression;

30 c) determining the pattern of the transcription factors of the NF- $\kappa$ B family in a nuclear extract of the culture;

35 d) identifying an agent which causes a significant alteration in the pattern wherein the altered pattern does not show a significant departure from the pattern characteristic of a comparable sample from a non-immunosuppressed individual of said mammalian species.

56. The method of Claim 55, wherein the agent is present *in vivo*.

57. A method of treating an immunosuppressed mammal by administering a therapeutically effective amount of an agent identified in claim 55 in a pharmaceutically acceptable diluent.

58. The method of claim 57 wherein the mammal is a human.

59. A kit for monitoring immunosuppression, said kit comprising in a separate container an antibody directed against a transcription factor of the NF- $\kappa$ B family and a means for detecting the formation of an antibody-antigen complex.

60. A substantially pure polypeptide that is formed by the degradation of the p50 member of the NF- $\kappa$ B transcription factor family *in vivo* in mammals that are immunosuppressed or have a tumor.


61. The polypeptide of claim 60 selected from the group consisting of p44 and p48.

62. An antibody directed to an amino acid sequence that is present in p50 but absent in a protein which replaces p50 in a nuclear extract of T lymphocytes obtained from an immunosuppressed mammal.


63. The kit of claim 60 wherein the antibody is an antibody according to claim 62.

I/5

**FIG. 1**




**FIG. 3**






2/5

**FIG. 2A**



**FIG. 2B**



3/5

FIG. 2C






FIG. 4A



5/5

FIG. 4B



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/02936

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/88, 93V, 534; 435/6, 7.24, 240.2, 436/501; 514/2; 530/350, 387.7, 388.2, 388.23, 389.1, 389.2, 828, 868; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched


Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS: search terms: Ochoa AC/au or loeffler CM/au and mca(W)38  
NF(W)KAPPA(W)B, antibod? or antiser?**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category* | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                          | Relevant to claim No. |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X         | Cancer Research, vol. 51, issued 15 April 1991, C.M. LOEFFLER ET AL, "Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis", pages 2127-2132. See page 2127, col. 2 and page 2128, col. 1. | 1-9, 36-37, 42        |
| X         | Journal of Immunology, vol. 144, no. 2, issued 15 January 1990, M. FURUE ET AL, "Coordinate expression of src family protooncogenes in T cell activation and its modulation by cyclosporine", pages 736-739. See abstract and page 736, col. 2              | 29-31, 33-34, 36, 41  |

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| * Special categories of cited documents:<br>"A" document defining the general state of the art which is not considered to be part of particular relevance<br>"E" earlier document published on or after the international filing date<br>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br>"O" document referring to an oral disclosure, use, exhibition or other means<br>"P" document published prior to the international filing date but later than the priority date claimed |  | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art<br>"G" document member of the same patent family |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                                                                       |                                                                                                                                               |
|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Date of the actual completion of the international search<br>22 June 1993                                             | Date of mailing of the international search report<br>24 JUN 1993                                                                             |
| Name and mailing address of the ISA/US<br>Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231 | Authorized officer: <br>DAVID SAUNDERS, PRIMARY EXAMINER |
| Facsimile No. NOT APPLICABLE                                                                                          | Telephone No. (703) 308-0196                                                                                                                  |

**A. CLASSIFICATION OF SUBJECT MATTER:**

IPC (5): A01N 63/00; A61K 37/02, 39/00; C07K 15/08, 15/14, 15/28; C12N 5/06, 15/12; C12Q 1/68; G01N 33/53

**A. CLASSIFICATION OF SUBJECT MATTER:**

US CL : 424/88, 93V, 534; 435/6, 7.24, 240.2, 436/501; 514/2; 530/350, 387.7, 388.2, 388.23, 389.1, 389.2, 828, 868; 536/23.5

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

- I. Claims 1-9, 35, 39-40 and 42-43, drawn to an immunosuppressive factor, methods of its use and products related thereto, classified in class 350/530+.
- II. Claims 10-29 and 41, drawn to methods of determining immunosuppression states and products via detection of TCR subunits or signal transduction proteins, classified in class 435/7.24.
- III. Claims 30-34, 36-38, and 44, drawn to method of identifying reversers of immunosuppression and to reversing products, classified in class 435/7.24.
- IV. Claims 46-63 drawn to methods of identifying immunosuppression by detecting expression of transcription factors, antibodies to transcription factors and kits, classified in class 435/6+.

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:  
(Telephone Practice)  
Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.